Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2015

An Applied Mathematics Approach to Modeling Inflammation:
Hematopoietic Bone Marrow Stem Cells, Systemic Estrogen and
Wound Healing and Gas Exchange in the Lungs and Body
Racheal L. Cooper
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Non-linear Dynamics Commons, Ordinary Differential Equations and Applied Dynamics
Commons, and the Partial Differential Equations Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/4312

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

c Racheal L Cooper, May 2016
All Rights Reserved.

i

AN APPLIED MATHEMATICS APPROACH TO MODELING
INFLAMMATION: HEMATOPOIETIC BONE MARROW STEM CELLS,
SYSTEMIC ESTROGEN AND WOUND HEALING AND GAS EXCHANGE IN
THE LUNGS AND BODY

A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

by
RACHEAL L COOPER
B.S., Virginia Commonwealth University - September 2008 to May 2011
M.S., Virginia Commonwealth University - September 2011 to December 2013

Director: Dr. Angela Reynolds,
Associate Professor, Department of Mathematics and Applied Mathematics

Virginia Commonwewalth University
Richmond, Virginia

ii

iii

I dedicate this thesis, in loving memory, to my father who raised me to always
have an inquisitive mind and seek knowledge around every corner. Your thoughtful
conversations and valuable insights proved inspiring throughout the years.

Acknowledgements

I wish acknowledge the numerous professors that assisted me thourought the
years. Without them, this would never have been possible. First, I would like to thank
Dr. Angela Reynolds, my dissertation advisor, as well as the rest of my committee:
Dr. Rebecca Heise, Dr. Rebecca Segal, Dr. Robert Diegelmann, and Dr. David
Edwards. Thank you all so much for the time and effort you put into making this
possible for me. I would also like to thank several other collaborators and professors:
Dr. Paul Brooks, Dr. Amir Toor, Dr. Catherine Roberts, Dr. Andrew Lewis, Dr.
Richard Hammack, Dr. Wes Cain, Dr. Norma Ortiz-Robinson, and Jenise Swall.
Thank you all for the opportunity to work with you.
I would also like to thank the family and friends who believed in me and encouraged me to stick with it: my aunt Elaine, my husband Zeb and his mother Vicki, and
my best friend Lacy.

iv

TABLE OF CONTENTS

Chapter

Page

Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

iv

Table of Contents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

v

List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

vii

List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

viii

Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

xi

1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1

2 Mathematical Model of Bone Marrow and Peripheral Blood Stem Cells .

6

2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2 Model Development . . . . . . . . . . . . . . . . . . . . . . . .
2.2.1 Normal State Model . . . . . . . . . . . . . . . . . . . . .
2.2.2 Modeling Filgrastim Dynamics . . . . . . . . . . . . . . .
2.2.3 Modeling Autologous Stem Cell Mobilization in Lymphoma
Patients . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.4 Modeling Plerixafor Dynamics . . . . . . . . . . . . . . .
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3.1 Modeling Allogeneic Stem Cell Mobilization Using Filgrastim in Normal Donors . . . . . . . . . . . . . . . . .
2.3.2 Modeling Autologous Stem Cell Mobilization Using Filgrastim in Patients . . . . . . . . . . . . . . . . . . . . .
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

.
.
.
.

6
10
10
15

. .
. .
. .

20
21
24

. .

24

. .
. .

29
32

3 Mathematical Model of Systemic Mediators in the Inflammatory Process of Wound Healing . . . . . . . . . . . . . . . . . . . . . . . . . . . .

37

3.1 Introduction . . . . . . . . . . . . . .
3.2 Model Development . . . . . . . . . .
3.2.1 Pathogen Equation . . . . . . .
3.2.2 Debris Equation . . . . . . . . .
3.2.3 Activated Macrophage Equation
v

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

.
.
.
.

.
.
.
.
.

.
.
.
.
.

37
39
40
42
43

. .

45

.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.

45
47
48
48
52
52
59
62

4 Mathematical Model of Gas Exchange in the Lungs and Body . . . . . .

65

3.3
3.4
3.5
3.6
3.7

3.8

3.2.4 Activated Neutrophil Equation . . . . . . . . . . . . . . .
Modeling the Effect of the Systemic Mediator Estrogen on Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Final Equation . . . . . . . . . . . . . . . . . . . . . . . . . . .
Initial Conditions . . . . . . . . . . . . . . . . . . . . . . . . .
Parameter Estimation . . . . . . . . . . . . . . . . . . . . . . .
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.7.1 Pt /P /N /M System without Systemic Mediators . . . . .
3.7.2 Effects of the Systemic Mediator Estrogen . . . . . . . . .
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . .
4.1.1 Biological background . . . . . . . . . . . . . . . . . .
4.1.2 Mathematical background . . . . . . . . . . . . . . . .
4.2 Previous Mathematical Model . . . . . . . . . . . . . . . .
4.2.1 Oxygen Dynamics in the Lung . . . . . . . . . . . . .
4.2.2 Carbon Dioxide Dynamics in the Lung . . . . . . . .
4.3 New Model Development . . . . . . . . . . . . . . . . . . .
4.3.1 Breathing and Mechanical Ventilation Waveforms . .
4.3.2 Modeling Hemoglobin and Oxygen in the Lung . . . .
4.3.3 Modeling Blood pH and Carbon Dioxide in the Lung
4.3.4 Closed Loop Breathing . . . . . . . . . . . . . . . . .
4.3.4.1 Well Mixing . . . . . . . . . . . . . . . . . . .
4.3.4.2 Gas Exchange in the Body . . . . . . . . . . .
4.3.4.3 Blood and Tidal Volume Variation . . . . . . .
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . .
5 Conclusion

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

65
65
68
70
71
76
77
78
80
85
86
86
87
90
91
98

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100

Appendix A Patient Data Used to fit the Mathematical Model Hematopoietic Bone Marrow Stem Cells . . . . . . . . . . . . . . . . . . . . . . . . . 102
A.1 Blood cell count data for donor patients treated with Filgrastim

. 102

Appendix B Abbreviations and Variables . . . . . . . . . . . . . . . . . . . 103
Appendix C Code . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
C.1 Mathematical Model of Hematopoiesis . . . . . . . . . . . . . . . . 104
vi

C.2 Mathematical Model of the Inflammatory Response . . . . .
C.3 Mathematical Model of Closed Loop Breathing . . . . . . . .
C.3.1 Calculation of Blood and Tissue Volumes in the Body .
C.3.2 Mathematical Model of Closed Loop Breathing . . . . .
C.3.3 Calculating Distributions for Tissue and Blood Volumes

.
.
.
.
.

.
.
.
.
.

.
.
.
.
.

110
111
111
112
119

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
Vita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146

vii

LIST OF TABLES

Table

Page

1

Steady state values of non-diseasaed donor model . . . . . . . . . . . . .

15

2

Parameter Values for the Non-Diseased Donor Fit . . . . . . . . . . . . .

16

3

Filgrastim Drug Parameters for Non-Diseased Donor Model with Filgrastim Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

20

4

Results of Sampling Non-Diseased Donor Fit . . . . . . . . . . . . . . . .

28

5

Results of Collection When Sampling Drug Parameter Space . . . . . . .

31

6

Reaction Kinetics of Resting and Activated Macrophages . . . . . . . . .

44

7

Model Parameters for the Local Background Immune Response for
Wound Healing Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

49

8

Parameter Set Data for Wound Healing Model . . . . . . . . . . . . . . .

53

9

Peak Time Data for Normal Conditions of Wound Healing Model . . . . .

55

10 Statistics for the Parameter Sampling of Estrogen Parameters . . . . . . .

60

viii

LIST OF FIGURES

Figure

Page

1

Model schematic of the cells involved in hematopoiesis. . . . . . . . . . .

11

2

Filgrastim drug dynamics . . . . . . . . . . . . . . . . . . . . . . . . . . .

17

3

Non-Diseased Donor Transients . . . . . . . . . . . . . . . . . . . . . . .

25

4

Non-Diseased Donor Data . . . . . . . . . . . . . . . . . . . . . . . . . .

26

5

Representative Sets for Diseased Patients Acquired from LHS Sampling .

27

6

Analysis of the Affect of Parameter Value Sampling . . . . . . . . . . . .

30

7

Analysis of the Affect of Parameter ksncf on Collection Numbers . . . . .

32

8

Accumulation of Stem Cells During Plerixafor Salvage . . . . . . . . . . .

33

9

Model Schematic for Macrophages and Neutrophils in the Wound Healing Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

41

10 Transients of Inflammatory Subsystem of Wound Healing Model . . . . .

54

11 Comparison of Transients and Representative Sets of Wound Healing
Model Parameter Sampling . . . . . . . . . . . . . . . . . . . . . . . . . .

54

12 Results of Accepted Parametere Set in Comparison with Maximum
Neutrophil Levels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

56

13 Validation of the Wound Healing Model by Removal of Inflammatory
Cell Populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

57

14 Analysis of Estrogen Parameters Contribution to the Percent Change
in Peak Time of Neutrophils and Macropages . . . . . . . . . . . . . . . .

61

15 Analysis of the Change in Transients Due to the Removal of Estrogen
from the Wound Healing Model . . . . . . . . . . . . . . . . . . . . . . .

62

ix

16 Diagram of Gas Exchange in the Human Lungs and Body . . . . . . . . .

67

17 Schematic of Gas Exchange in the Human Lung for Previous Mathematical Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

71

18 Model Schematic for Gas Exchange in the Human Body . . . . . . . . . .

79

19 Gas Exchange in the Lung Normal and Ventilation Waveforms . . . . . .

81

20 Illustration of Well Mixing of Lung RU Outputs . . . . . . . . . . . . . .

88

21 Results of the Gas Exchange Model–Oxygen . . . . . . . . . . . . . . . .

94

22 Results of the Gas Exchange Model–Carbon Dioxide . . . . . . . . . . . .

95

23 Results of the Gas Exchange Model Under Mechanical Ventilation
Conditions–Oxygen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

96

24 Results of the Gas Exchange Model Under Mechanical Ventilation
Conditions–Carbon Dioxide . . . . . . . . . . . . . . . . . . . . . . . . . .

97

x

Abstract
AN APPLIED MATHEMATICS APPROACH TO MODELING
INFLAMMATION: HEMATOPOIETIC BONE MARROW STEM CELLS,
SYSTEMIC ESTROGEN AND WOUND HEALING AND GAS EXCHANGE IN
THE LUNGS AND BODY
By Racheal L Cooper
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016.

Director: Dr. Angela Reynolds,
Associate Professor, Department of Mathematics and Applied Mathematics
Mathematical models apply to a multitude physiological processes and are used
to make predictions and analyze outcomes of these processes. Specifically, in the
medical field, a mathematical model uses a set of initial conditions that represents
a physiological state as input and a set of parameter values are used to describe
the interaction between variables being modeled. These models are used to analyze
possible outcomes, and assist physicians in choosing the most appropriate treatment
options for a particular situation. We aim to use mathematical modeling to analyze
the dynamics of processes involved in the inflammatory process.
First, we create a model of hematopoiesis, the processes of creating new blood
cells. We analyze stem cell collection regimens and statistically sample parameter
space in order to create a model accounts for the dynamics of multiple patients. Next,
we modify an existing model of the wound healing response by introducing a variable
xi

for two inflammatory cell types. We analyze the timing of the inflammatory response
and introduce the presence of systemic estrogen in the model, as there is evidence that
the presence of estrogen leads to a more efficient wound healing response. Last, we
mathematically model the gas exchange process in the lungs and body in order to lay
the foundation for a model of the inflammatory response in the lung under conditions
of mechanical ventilation. We introduce normal and ventilation breathing waveforms
and a third state of hemoglobin in a closed loop partial differential equations model.
We account for gas exchange in the lung and body compartments in addition to
introducing a third discretized well-mixing compartment between the two.
We use ordinary and partial differential equations to model these systems over
one or more independent variables, as well as classical analysis techniques and computational methods to analyze systems. Statistical sampling is also used to investigate
parameter values in order for the mathematical models developed to account for
patient-to-patient variability. This alters the traditional mathematical model, which
yields a single set of parameter values that represent one instance of the physiology,
into a mathematical model that accounts for many different instances of physiology.

xii

CHAPTER 1

INTRODUCTION

Mathematical models of physiological processes are useful tools that can aid physicians in making decisions about patient care. The in depth design and analysis of
these models in necessary in order to ensure that these models can be used effectively.
In this thesis, we develop several mathematical models that describe various stages
of the inflammatory response and various biological systems in which inflammation
is present. While the inflammatory response is necessary to prevent infection and
disease, an impaired inflammatory response can lead to the presence of chronic inflammation and can lead to problems in basic processes required for survival. For
example, an emergent trauma patients’ natural immune response oftentimes culminates into an impaired immune response that delays the deposition of collagen, an
essential part of the wound healing process, which can lead to a life threatening septic
situation and exacerbate the original trauma. Also, the presence of inflammation in
lung capillaries can cause the swelling of the tissue barrier that decreases the oxygenation of blood in the lung capillary or even completely causes oxygenation to be
impossible. Therefore, damage caused by this natural immune response can accumulate over multiple lung breath cycles and lead to improper oxygenation of the body
tissue. On the other hand, the presence of systemic mediator estrogen in the wound
healing processes modulates the influx of immune cell populations in such a way that
wound healing may occur more efficiently. There are many driving factors in successful inflammatory response, and so the mathematical modeling of these processes can
aid physicians in making choices that could benefit patient care.

1

We begin by developing an ordinary differential equations model of the origin of
blood cells: erythrocytes, white blood cells, and thrombocytes/platelets. These cell
types originate in the bone marrow as hematopoietic stem cells, which differentiate
into committed progenitor cells that proliferate and differentiate into mature progenitors in the bone marrow (BM). From the bone marrow, these mature progenitors
move out into the peripheral blood (PB) where erythrocytes are responsible for oxygenating body tissue and white blood cells and platelets function in wound healing
and the inflammatory processes [1]. In addition to the presence of these blood cell
types in the PB, stem cells also move from the BM into the PB where they lie dormant
in the cycling PB and populate stem cell pools in other parts of the body, such as the
spleen. The function of cells involved in this process are adversely affected in cancers
of the blood [2, 3, 4]. Specifically, we will focus on lymphoma which is marked by the
presence of increased amount of lymphocytes in the PB and accumulation of lymphocytes in the lymph nodes [3]. The treatment of patients with lymphoma involves a
combination of chemotherapy and radiation followed by transplantation of PB stem
cells collected prior [5, 6]. Drug treatments are used during the collection process,
which occurs before chemotherapy and radiation, to facilitate the movement of stem
cells into the PB, in addition to other dynamics. Following drug treatment, stem
cells are collected from patients that will be used later for transplantation in order to
repopulate the bone marrow stem cells [6]. Oftentimes, this collection is unsuccessful,
i.e. not enough cells are obtained from the collection process, and the resulting stem
cell population is not adequate to repopulate the patient’s bone marrow stem cells
following chemotherapy treatment. If this is the case, the patient undergoes a second
drug treatment regimen and subsequent collection process. Physicians primarily only
use this second drug in poor mobilizaton circumstances due to its substantial cost [7,
8]. A mathematical model of this process could prove useful in determining which
2

patients would benefit from using the second drug despite the cost and reduce the
time between diagnosis and treatment of disease.
Next, we modify an existing ordinary differential equations model of inflammation and subsequent collagen deposition in the wound healing process. We begin by
introducing two variables that represent neutrophils and macrophages individually.
Specifically, these cell populations have different influx dynamics and are activated
by different cell types in the wound. This modification is essential in that it allows
for the inclusion of the systemic mediator estrogen, which is known to affect the two
populations differently [9, 10, 11]. We validate this model using simulations with
the removal of each inflammatory cell population. We then use the model to explore
how the removal of estrogen from the system alters the wound healing process. Originally, the model was created based on dynamics of female mice where estrogen is
present. The modification of the parameter values accounts for the lack of estrogen
and validates the model based on the change in neutrophil levels when estrogen is
present. Similar to the previous model, we also sample parameter space in order to
create a population of patients that have estrogen present and estrogen absent. This
model is designed to be used by physicians to study the presence of system estrogen
in modulating the wound healing response in such a way that the outcomes of healing
are more effective.
Last, we modify an existing partial differential equations model of blood flow and
gas exchange in the lung capillary to account for a more accurate airflow waveform
in the airspace for normal breathing and mechanical ventilation breathing. It is
common for hospital patients to require the use of mechanical ventilation, which is
known to be potential harmful to the lung if too much air is forced into the lung during
inhalation. If this occurs, the individual alveolus in the lung can be stretched to a
point where the damages causes inflammation to enter into the capillary and cause
3

the alveolus to shunt and not be involved in the breathing process. Accumulation of
damage because of this can be detrimental to the patient [12]. In order to do this, we
introduce multi-state hemoglobin dynamics into the existing mathematical model [13].
An unsaturated state of hemoglobin is introduced to create a model that accounts
from three states of hemoglobin dynamics: nonoxygenated, partially oxygenated, and
fully saturated). This modification will create a model that allows for the inclusion of
a non-oxygenated hemoglobin state, and thus a better mathematical representation
of the adverse effects of an impaired inflammatory response in the lung.
In addition to this, we create a 200 spacial unit model of gas exchange in the body.
We account for oxygen loss from the blood to the tissue and the uptake of carbon
dioxide from the tissue into the blood. After the blood flows through the body, it
exits the body compartment in a low oxygen state and feeds directly into a 20 spacial
unit lung compartment, where the carbon dioxide is lost to the airspace and more
oxygen is gathered to be dispersed through the body. When the oxygenated blood
leaves the lung, it feeds into a well mixing compartment which allows for the mixing
of oxygen that comes from different parts of the lung. Once mixed, the oxygen-rich
blood enter back into the body and the process continues. Last, we include a model
of pH in the blood of the lungs and body that can be included in the full model
to account for the presence of carbon dioxide in the bicarbonate buffer system, the
main driver of pH regulation in the body. The presence of carbon dioxide affects the
hemoglobin saturation rate in the blood, and therefore the inclusion of these dynamics
in the model are important to the overall model of gas exchange in the capillaries of
the lung [14]. This mathematical model can be used to analyze the accumulation of
damage due to inflammation in the mechanical ventilation situation and/or the effect
of the presence of inflammation in the lung in disease states such as COPD.
We use mathematical modeling techniques common used in applied mathematics
4

and mathematical biology to analyze and learn more about physiological systems and
processes that would otherwise require expensive studies and cause harm to patients.
We use classical numerical analysis techniques to analyze the systems and LatinHypercube Sampling (LHS) techniques to sample parameter space of biologicallysignifiant parameters. We sample the parameter space uniformly and we choose
relevant ranges on the parameter values, and after a set is selected, we analyze the
outcome to ensure biologically relevant dynamics. If the outcome of the simulation of
the parameter set is desirable, it is accepted as a possible set to represents a patient.
In the future, the work could be used to study and analyze specific possible outcomes
based on information obtained about individual patients. If this can be successfully
achieved, these models can then be used to predict whether or not patients will
respond to treatment or need expensive intervention early on and thus shorten the
time between patient admittance and diagnosis and treatment.

5

CHAPTER 2

MATHEMATICAL MODEL OF BONE MARROW AND
PERIPHERAL BLOOD STEM CELLS

2.1

Introduction
Hematopoietic malignancies such as leukemia, multiple myeloma, and lymphoma

are treated using combinations of chemotherapy, radiation, and hematopoietic stem
cell transplantation [3, 4, 2]. These cancers often recur after treatment causing patients to require multiple treatments [15]. Therapy for relapsed hematological malignancies often involves collection of functional hematopoietic stem cells (HSC) in order
for transplantation after marrow-ablative chemotherapy and radiation have been administered [16]. In this paper, we mathematically model mobilization and collection
of HSCs with commonly used stem cell mobilizing agents in order to aid physicians
in the treatment of cancers of the blood.
The hematopoietic stem cell population distributed throughout the bone marrow
(BM) is responsible for maintaining normal levels of terminally differentiated cell
populations, such as erythrocytes, leukocytes, lymphocytes and platelets [17, 18, 19,
2]. HSCs that differentiate into the committed hematopoietic progenitors undergo
maturation to become the various cell populations circulating in the blood. Within
the bone marrow niche, cell types such as osteoblasts, osteoclasts, and other stromal
cell populations support HSCs. After differentiation, the matured cells migrate out
of the bone marrow into peripheral circulation [20].
Lineage-specific growth factors influence the differentiation of HSCs into differentiated cell types. For example, erythropoietin levels increase when oxygen levels
6

in the body decrease, which is a specific signal for erythrocyte progenitor cells and
increases erythrocyte levels [2, 21]. Similarly, thrombopoietin regulates the production of platelets, and monocyte colony-stimulating factor and granulocyte-monocyte
colony-stimulating factor regulates the production of monocytes. Granulocyte colonystimulating factor (G-CSF) regulates the production of neutrophils [2, 21, 22, 4]. GCSF also stimulates the migration of CD34+ HSC into the peripheral circulation [23,
24]. Cell surface expression of CD34+ indicates a population of cells that contain
true repopulating HSC is the primary indicator of the numbers HSCs present [18, 21,
25].
We will focus on the mechanisms of the maintenance of red blood cells, white
blood cells, platelets, and circulating CD34+ cells, also referred to as peripheral blood
stem cells (PSC), under normal homeostatic conditions. We will also analyze CD34+
stem cell mobilization, collection, and transplantation in normal patients, and diseased patents under drug treatments. To do this, we must account for two different
progenitor cell types in addition to the populations of stem cells in the BM, which is
required to accurately capture homeostatic concentrations of these cell types in the
peripheral blood. In addition, we study the mobilization process in the presence of
Filgrastim, recombinant G-CSF, and its use in combination with Plerixafor, a CXCR4
antagonist with stem cell mobilizing properties commonly used in patients that are
resistant to Filgrastim. Autologous stem cell transplantation (ASCT), where patients
with lymphoma donate stem cells for themselves, is a common form of transplantation, and will be the focus of our mathematical modeling of stem cell mobilization
in patients. ASCT is used for patients with hematological malignancies such as lymphoma and multiple myeloma [3, 16, 26].
Patients that undergo ASCT are first given Filgrastim, which increases the proliferation and differentiation of HSCs within the bone marrow, and mobilization of
7

HSCs into the peripheral blood (PB) [27]. In a process called apheresis, PSCs are collected ex vivo, a process taking up to six hours per day and can be carried out for up
to four days until the target number of PSC is collected [28, 29, 30]. Patients whose
stem cell mobilization and collection yield around 5 million CD34+ cells/kg (around
430 million total CD34+ cells) are considered successful collectors and are eligible for
transplantation following chemotherapy and radiation treatments. If the total cell
counts are not high enough, the donor is often treated with Plerixafor to enhance
the mobilization of HSCs to reach the targeted collection goal [31, 32, 33]. Plerixafor
is expensive so it is not used in patients unless Filgrastim-mediated collection is not
successful.
In this paper, we will develop a mathematical model to study the dynamics of
hematopoietic cell population growth and differentiation [34, 35] and how the two
drugs discussed effect mobilization [36, 37, 38]. There exist several mathematical
models of the dynamics in the HSC system in conjunction with GCS-F kinetics in
humans, but none with the dynamics of Filgrastim used in conjunction with Plerixafor. One model, developed by Tibken and Hofer (1996), accounts for stem cells
numbers and relative changes during radiation treatment of leukemia. The model
uses patient data but considers cell numbers after transplantation and does not take
drug treatments into consideration [39]. A model developed by Steinbach et al. considers granulopoiesis with BM maturation and reserve pools of stem cells in canines
[40]. Both consider perturbations of cell types in the system and how this may effect
granylopoiesis.
A series of articles [41, 42, 21] discuss a compartmental model of hematopoiesis
that accounts for differentiation of HSCs into erythrocytes, neutrophils, and platelets.
This model uses time delay terms to account for the proliferation phase of the cell
types mentioned. These articles discuss the presence and importance of oscillations
8

in the system and model the effect of treatment with Filgrastim using simulations.
The results are compared to data in patients with lymphoma. In addition to this
model, numerous other models exist that focus on the levels of neutrophils following
Filgrastim treatment and focus on the presence of neutropenia developing during the
treatment process [43]. Our model aims to account for dynamics of the growth and
differentiation of the three major circulating cell populations and how they react to
drug levels and the collection process without time delay differential equations and
to account for various in this response within a population of patients.
We aim to create a model to account for the stem cell mobilization process
by instead accounting for two different types of bone marrow progenitors: committed progenitors that result from HSCs and those that are committed to becoming a
specific type of functional blood cells, described in the following section. These committed progenitors then mature in the BM before migrating to the PB compartment
and function as per their cell type. First, we account for this process in a normal person, someone who would not normally require transplantation and fit to data from
normal individuals that donated their stem cells. Then, we sample the parameter
space, using the normal person’s parameter set as a starting point, in order to model
patients with lymphoma. We accept resulting parameter sets based on the change
in dynamics that is biologically relevant to the disease state and we simulate drug
treatment, resulting mobilization, and subsequent collection of each of these patients.
The resulting collection can then be classified as either successful or unsuccessful
collectors. Sampling is then used to evaluate varying responses to Filgrastim and
treatment of poor collectors with Plerixafor is simulated.
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2.2

Model Development

2.2.1

Normal State Model

To model the process of hematopoiesis, we develop a system of ordinary differential equations that account for the interaction of cells within both the BM and PB
compartments. In the BM compartment we model CD34 +HSCs (C), the committed
platelet/thrombocyte (Lc ), erythrocyte (Rc ), and leukocyte (Nc ) lines, and fully differentiated cells for each cell line (Lp , Rp , and Np , respectively). In the PB, we model
the blood components of these lines (Lb , Rb , and Nb , respectively) and the CD34+
cells that arise from the BM (P ). The schematic in Figure 1 shows the components of
the hematopoiesis process included in this model. Several cell types that are known
to be present within the BM are omitted from the model, such as lymphocytes and fat
cells, in order to capture the dynamics of the cell lines that function in hematopoiesis.

HSC dynamics are modeled by Equation (2.1). Their proliferation is modeled by
the first term

sc C
.
1+(R+L+N )/c∞

The denominator inhibits the proliferation rate sc by the

amount of cells in the blood (the sum of Rb , Nb , and Lb ), where c∞ controls the ability
of these cells to modulate this proliferation. The second term, −(kcrc + kclc + kcnc )C,
accounts for the differentiation of HSCs into subsequent committed cells, erythrocytes,
lymphocytes, and neutrophils, respectively at rates kcxc , and is negative to indicate a
loss of HSCs when committed cells differentiate into precursor cells. The third term,
kcp
(P
vm

− C), accounts for the movement of BM stem cells into the PB at rate kcp ,

where vm is the relative size of the BM compartment. Division by vm scales the rates
of differentiation to account for the relative change in concentration due to the cells
moving between compartments. A diffusion type term is used here in order to capture
the ability of the stem cells in the PB to repopulate the HSCs. The last term, −µc C,
10

Fig. 1. Model schematic outlining the progression of cell populations in the BM and PB
compartments. In the BM compartment, the solid line indicates proliferation and
short-dashed line indicates differentiation. The long-dashed line indicates movement
from the BM into the PB that occurs in both directions. The red lines with bars
indicate the inhibitory effect of blood cells on their progenitors in the bone marrow.
A single star indicates interactions with processes that are effected by Filgrastim
and a double star indicates interactions that are effected by both Filgrastim and
Plerixafor.
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models the natural decay of HSCs.

dC
sc C
kcp
=
− (kcrc + kclc + kcnc )C +
(P − C) − µc C
dt
1 + (Rb + Nb + Lb )/c∞
vm

(2.1)

The equations that model the remainder of cell populations in the bone marrow have similar forms, since all cells progress through similar dynamics, committed
cells in the bone marrow (Rc , Nc , and Lc ) to terminally differentiated erythrocytes,
white blood cells, and platelets (Rm , Nm , and Lm , respectively). The terminally
differentiated cells can then move out of the BM and into the PB. They each have
uni-directional movement through and out of the bone marrow. Committed cells, differ from progenitor cells in that they proliferate, first term of Equations (2.2)-(2.4).
The source rate is modulated by the peripheral blood, similar to the first term in the
HSC equation. However, instead of being modulated by the size of the entire blood
compartment, it is modulated only by the cell population in the PB down the line
from itself. For example, the proliferation of committed erythrocytes (Rc ) is modulated by the amount of erythrocytes present in the blood (Pb ). The second term in
each equation accounts for the differentiation of HSCs into each committed cell population. The third term models the differentiation of committed cells into progenitor
cells. Each equation also has a natural decay (last term) to account for programmed
cell death.

dRc
src Rc
=
+ kcrc C − krcm Rc − µrc Rc
dt
1 + Rb /r∞
dLc
slc Lc
=
+ kclc C − klcm Lc − µlc Lc
dt
1 + Lb /l∞
dNc
snc Nc
=
+ kcnc C − kncm Nc − µnc Nc
dt
1 + Nb /n∞
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(2.2)
(2.3)
(2.4)

Equations (2.5)-(2.7) represent the three precursor cell types in the bone marrow,
and have similar form as Equations (2.2)-(2.4). They do not proliferate like committed
cells, instead they rely on the differentiation of committed cells. This process is
modeled by the first term of Equations (2.5)-(2.7). The second term, accounts for
the movement of each precursor cell into the peripheral blood, where they become
functioning cells. The difference in sizes of each compartment scales the parameter,
as before. The last term of equation accounts for natural decay of the precursors
cells.

dRm
krmr
= krcm Rc −
Rm − µrm Rm
dt
vm
dLm
klml
= klcm Lc −
Lm − µlm Lm
dt
vm
dNm
knmn
= kncm Lc −
Nm − µnm Nm
dt
vm

(2.5)
(2.6)
(2.7)

The PB equations that arise from the movement of precursor cells are given in
Equations (2.8)-(2.10). The first term in each accounts for the movement of precursor
cells out of the BM decay and the final models natural decay. The parameter vb , is
used like vm above , to scale the change concentration due to the shift of cells to the
blood compartment. The ratio of vb to vm is determined by the ratio of the blood
volume to bone marrow volume in a healthy individual.
dRb
krmr
=
Rm − µr Rb
dt
vb
dLb
klml
=
Lm − µl Lb
dt
vb
dNb
lnmn
=
Nm − µn Nb
dt
vb

(2.8)
(2.9)
(2.10)

Last, we model the presence of CD34+ cells in the PB by Equation (2.11).
CD34+ cells in the blood will proliferate, modeled by the first term,
13

sp P
.
1+(C+P )/p∞

The

proliferation is modulated by the amount of HSCs in the BM and the amount of
CD34+ cells in the PB. The second term in this equation is similar to the third term
in Equation (2.1), where HSCs move out into the PB and the last models natural
decay.
dP
dt

=

sp P
kcp
+
(C − P ) − µp P
1 + (C + P )/p∞
vb

(2.11)

We refer to this model as the normal donor model, as it accounts for dynamics in a
healthy person. The parameters were chosen to match physiological blood cell counts,
erythrocytes account for 3-4 million cells/µL of PB, white blood cells account for 3-8
thousand cells/µL of PB, and platelets account for 150-250 thousand cells/µL of the
PB. We allow the range of PSCs to be broad, from 1-15 cells/µL, because our normal
donor data shows variability in these levels for healthy individuals. Less is known
about specific concentration of cells in the BM, so these dynamics were fit based on
relative numbers to each other. For example, the ratio of committed erythrocytes to
committed white blood cells was fit to be about 1:5. Also, because erythrocytes in
the blood have a higher half-life than other cells present the numbers of committed
erythrocytes in the BM are fit to have the lowest concentration.

Table 1 shows the resulting steady state of the normal donor model, which corresponds to homeostasis in a healthy person. The percentage contribution of cell types
in the BM in Table 1 is calculated assuming that 60% of BM is not accounted for in
the model. This portion of the BM includes cells that become lymphocytes and other
immune cells not accounted for, as well as the portion of BM that is not functioning
in the process of hematopoiesis, such as fat cells. The parameters that give rise to
14

Variable

Steady State Value
(cells/µ L)

Effective Percentage
of Compartment

HSCs (C)

222.88 × 103

8.41%

Committed RBCs (Rc )
Committed Platelets (Lc )
Committed WBCs (Nc )

101.83 × 103
243.32 × 103
480.18 × 103

3.84%
9.17%
18.10%

Differentiated RBCs (Rm )
Differentiated Platelets (Lm )
Differentiated WBCs (Nm )

41.56 × 103
31.74 × 103
39.47 × 103

1.57%
1.20%
1.48%

PSCs (P )
RBCs (Rb )
WBCs (Nb )
Platelets (Lb )

0.00245 × 103
3, 325.09 × 103
4.93 × 103
222.16 × 103

< 0.001%
93.61%
0.14%
6.25%

Table 1. Steady state values and percentages of cells in associated compartments for
the non-diseased donor model. In the percentage of cell types, the total BM
is assumed to include cell types modeled here and fat cells, other parts of the
bone marrow present that do not function in the process of hematopoiesis,
and those that make up the cell line that contributes to lymphocytes in the
blood. We assume that 40% of the blood is accounted for.

the homeostasis state are given in Table 2. While a healthy person wound not likely
undergo treatment, we use the normal donor model to set a baseline for continuing
model development. In particular, the steady state fit will be used as a starting point
for parameter sampling used to create a population of individuals with lymphoma.
2.2.2

Modeling Filgrastim Dynamics

We continue the modeling process by introducing the drug Filgrastim (Df ) into
the system. Filgrastim effects the proliferation rate of HSCs and committed neutrophils in the BM, as well as the movement of HSCs into the PB. This interaction
is indicated in Figure 1 by a single star. The drug also causes the committed cell
populations to move into the periphery where they are considered among the CD34+
cell population, indicated in Figure 1 by gray-dashed arrows.
We track relative Filgrastim drug effectiveness using Equation (2.12). The dosing
of the drug is modeled using Sm (t) = 1/(1 + e−50(t0 −mod(t,t0 +tx )) ). This is function is
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Parameter

Value

Description

sc
src
slc
snc
sp
kcp
kcrc
kclc
kcnc
krcm
klcm
kncm
krmr
klml
knmn
µc
µp
µrc
µlc
µnc
µrm
µlm
µnm
µr
µl
µn
vb
vm

3.25
12.2
3.8
3.4
3.0
0.0001
0.2
1.2
0.05
4.0
0.9
0.3
8.0
3.5
0.9
0.45
2.0
3.1
2.0
2.0
1.8
3.4
3.4
0.02
0.1
0.4
5
1

c∞

5000

r∞

4000

l∞

200

n∞

10

p∞
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Source rate of HSCs
Source rate of committed RBCs
Source rate of committed Platelets
Source rate of committed WBCs
Source rate of PSCs
Rate at which HSCs move into the periphery
Rate at which HSCs differentiate into committed RBCs
Rate at which HSCs differentiate into committed Platelets
Rate at which HSCs differentiate into committed WBCs
Rate at which committed RBCs become pre-RBCs
Rate at which committed Platelets become pre-Platelets
Rate at which committed WBCs become pre-WBCs
Rate at which pre-RBCs move into the PB
Rate at which pre-Platelets move into the PB
Rate at which pre-WBCs move into the PB
Natural decay rate of HSCs
Natural decay rate of PSCs
Natural decay rate of committed RBCs in the BM
Natural decay rate of committed Platelets in the BM
Natural decay rate of committed WBCs in the BM
Natural decay rate of committed pre-RBCs in the BM
Natural decay rate of committed pre-Platelets in the BM
Natural decay rate of committed pre-WBCs in the BM
Natural decay rate of RBCs in the PB
Natural decay rate of Platelets in the PB
Natural decay rate of WBCs in the PB
Relative size of the PB compartment
Relative size of the BM compartment
Controls the effectiveness of the amount of RBCs in the PB to regulate the
source of committed RBCs
Controls the effectiveness of the amount of RBCs in the PB to regulate the
source of committed RBCs
Controls the effectiveness of the amount of Platelets in the PB to regulate
the source of committed Platelets
Controls the effectiveness of the amount of WBCs in the PB to regulate the
source of committed WBCs
Controls the effectiveness of the amount of HSCs in the BM and PSCs in the
PB to regulate the source of PSCs in the PB

Table 2. Parameter values for the steady state dynamics of a non-diseased donor. Use
of these parameter values yields homeostasis in the non-diseased donor, values
given in Table 1.
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Drug Dynamics

Drug Effectiveness

1.5

1

0.5

0
0

2

4

6
Treatment Day

8

10

12

Fig. 2. Filgrastim drug dynamics that correspond to t0 = 6, tx = 18, xf = 1.5,
τ1f = 0.2 and τ2f = 0.025. Filgrastim was given for eight doses starting at day
two.
one for the six hours a day that the drug is entering the system and zero otherwise. It
is smooth approximation to the Heaviside function with the mod function controlling
the on and off each day. In practice, the drug is injected instantaneously, however,
since subcutaneously injected drug will be absorbed slowly over time, we use Sm (t)
to model the uptake of drug into the body as happening over the span of six hours.
The value t0 = 6 indicates drug uptake time in hours and tx = 18 is the remainder
of the day. The two terms control the accumulation of drug up to the value xf . The
second terms controls the decay of the drug in the system. Figure 2 shows Filgrastim
drug effectiveness versus time with eight doses starting the first administration on
day two.

dDf
dt

= τ1f Df (xf − Df )Sm (t) − τ2f Df
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(2.12)

In order to model the inclusion of Filgrastim in the system described previously,
we modify Equations (2.1)-(2.4) and Equation (2.11). Filgrastim is known to increase
the rate of proliferation and movement of HSCs out of the BM, and to increase the
proliferation rate of committed neutrophils in the BM and CD34+ cells in the PB[4,
44, 37, 45, 46].. Therefore, the parameters sc , sp , kcp , and snc in the original model are
changed. Specifically, the parameters are increased by a factor (1+kxf Df ) determined
by the level of drug in the system. For example, the source of HSCs in the BM, sc is
increased by an additive amount determined by the constant kscf multiplied by the
level of Filgrastim in the system There is a corresponding parameter that modulates
the effect of the drug for all four parameters. The updated equations are given in
Equations (2.13)-(2.17).
In addition to this rate increase, Filgrastim also initiates the movement of committed cells form the BM into the PB where they become part of the CD34+ cell
population. This is modeled by the inclusion of an additional term in Equations
(2.14)-(2.16) for the lost of the cells from the committed cells and three additional
terms in the PB stem cell equation (Equation (2.17)), associated with each committed
cell type.
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dC
dt

=

sc C(1 + kscf Df )
kcp (1 + kcpf Df )
− (kcrc + kclc + kcnc )C +
(P − C)
1 + (Rb + Nb + Lb )/c∞
vm
−µc C

dRc
dt
dLc
dt
dNc
dt
dP
dt

(2.13)

src Rc
krcpf Df
+ kcrc C − krcm Rc − µrc Rc −
Rc
1 + R/r∞
vm
slc Lc
klcpf Df
=
+ kclc C − klcm Lc − µlc Lc −
Lc
1 + L/l∞
vm
(snc + ksncf Df )Nc
kncpf Df
=
+ kcnc C − kncm Nc − µnc Nc −
Nc
1 + N/n∞
vm
sp P
kcp
krcpf Df
=
+
(C − P ) − µp P +
Rc +
1 + (C + P )/p∞
vb
vb
klcpf Df
kncpf Df
Lc +
Nc
vb
vb
=

(2.14)
(2.15)
(2.16)

(2.17)

To mathematically model the collection process, we assume the patient has two
resting days, where they are in steady state and the doctors have time to run tests
establish baseline values and potentially predict difficulties to come. We then model
the injection of Filgrastim in the system for six hours a day for four days, during which
time cells react to the drug and reach biologically relevant values based on known
responses to the drug. After four days the collection process is started. Removal
of the cells is modeled in the Lb , Nb , and P equations as exponential decay based
on the concentration of cell type present during the collection process. During the
collection process, erythrocytes are returned to the PB, so a decay is not included
in this equation. Removal occurs for six hours a day for four days, during which
time Filgrastim drug administration is continued. Afterwards, collection ends and
Filgrastim drug administration is halted and the concentrations return to steady
state.
The normal donor model with Filgrastim treatment is fit such that adequate
collection number are obtained in up to three days and fit to data in which healthy
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Parameter

Value

kscf

0.09

ksncf

2.5

krcpf

0.0025

klcpf

0.0025

kncpf

0.0025

Description
Effect of Filgrastim on the proliferation of HSCs (sc )
Effect of Filgrastim on the movement of HSCs into the PB
(kcp )
Causes committed RBCs to move intot he periphery where
they become CD34+ cells in the presence of Filgrastim
Causes committed Platelets to move into the periphery where
they become CD34+ cells in the presence of Filgrastim
Causes committed WBCs to move into the periphery where
they become CD34+ cells in the presence of Filgrastim

Table 3. The parameters controlling Filgrastims effect on the non-diseased donor system are given. These parameters are unit-less multipliers applied to the level
of drug in the system and affect only parameters that modulate processes
affected by Filgrastim.

individuals are donating stem cells for a bank of cells that can be accessed by physicians. This gives rise to the drug parameters in Table 3. With these parameters the
normal donor model yields approximately 440 million CD34+ cells collected in four
days. These parameters are unit-less scalars on drug effectiveness that control the
strength of the given model components in response to the drug, indicated in the
description column.

2.2.3

Modeling Autologous Stem Cell Mobilization in Lymphoma Patients

Next, we modify the parameters in the model to represent the steady state of a
population of patients with lymphoma that plans to undergo ASCT. Latin-Hypercube
Sampling (LHS) of the parameter space around the chosen representative set for a
normal donor is performed in order to obtain sets of parameter values that correspond
to patients with lymphoma [47]. We use uniform sampling of parameters believed to
be governing the diseased state with the minimum and maximum of the distribution
being 15% less and 15% more than the parameter’s value in the normal donor model
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fit. We sample sc , kpc , kcpr , kcpn , and kcpl , which are the parameters that control the
rate of proliferation of HSCs in the BM. All other parameters are held constant to
the normal donor values throughout parameter selection and subsequent simulations.
Parameter sets are considered to represent a diseased individual if the following
hold:
• The functional size of bone marrow in the lymphoma patient (Tf l ) is smaller
than that of the normal donor Tf n : Tf l < Tf n [48].
• The steady state value of erythrocytes in the blood of the lymphoma patient is
within [3 × 106 , 8 × 106 ] cells/µL for the resulting transients[1].
• The steady state value of platelets in the blood of the lymphoma patient is
within [100 × 103 , 600 × 103 ] cells/µL for the resulting transients[1].
If a parameter set created by LHS passes these conditions, the set is accepted
and simulations for collection are run. The parameter set can then be classified as
one that yields adequate CD34+ cell count for transplantation (satisfactory collection
set) or one that does not (poor collection set). Establishing a collection of patients is
a useful tool because it enables us to look at various ways in which the disease could
manifest and still give rise to biologically relevant dynamics and explore how these
differences in the disease effect the patient’s ability to donate HSCs.
2.2.4

Modeling Plerixafor Dynamics

Despite treatment with Filgrastim and collection for four days and beyond, collection numbers of PSC is occasionally too low. In this situation, the lack of PSC in
collection yields would prove detrimental to patients in the transplantation process,
and, therefore, treatment would be postponed. Doctors rely on the use of Plerixafor,
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and expensive yet effective drug to aid the stem cell mobilization process [49]. Plerixafor (Dp ) is always given in conjunction with Filgrastim and the treatment process
is restarted in order to increase mobilization and obtain a collection yield that is adequate for transplantation. The increased movement of HSCs into the PB this causes
is indicated in Figure 1 by double stars. Plerixafor effectiveness is modeled similar to
Filgrastim effectiveness. Equation (2.18) has the identical form of Equation (2.12),
but the xp and τ parameters governing the dynamics will be different (xp = 1.1,
τ1p = 0.2 and τ2p = 0.025). The other parameters remaining the same since the drug
administration is the same.
dDp
= τ1p Dp (xp − Dp )Sm − τ2p Dp
dt

(2.18)

In order to model the effect of Plerixafor on the cells, we introduce a second sum
on the factor kcp (1 + kcpf Df ) in the equations for BM and PB stem cells. The term
becomes kcp (1 + kcpf Df + kcpc Dp ), where the parameter kcpc modulates the effect of
Plerixifar in combination with Filgrastim.
The final set of equations modeling the process of hematopoiesis with the effects
of Filgrastim and Plerixafor drug dynamics is given in Equations (2.19)-(2.31).
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dC
dt

=

dRc
=
dt
dLc
=
dt
dNc
=
dt

dRm
=
dt
dLm
=
dt
dNm
=
dt

dRb
dt
dLb
dt
dNb
dt
dP
dt

sc C(1 + kscf Df )
− (kcrc + kclc + kcnc )C
1 + (Rb + Nb + Lb )/c∞
kcp kcp (1 + kcpf Df + kcpc Df )
(P − C) − µc C
vm
src Rc
krcpf Df
+ kcrc C − krcm Rc − µrc Rc −
Rc
1 + Rb /r∞
vm
slc Lc
klcpf Df
+ kclc C − klcm Lc − µlc Lc −
Lc
1 + Lb /l∞
vm
(snc + ksncf Df )Nc
+ kcnc C − kncm Nc − µnc Nc
1 + Nb /n∞
kncpf Df
−
Nc
vm
krmr
krcm Rc −
Rm − µrm Rm
vm
klml
klcm Lc −
Lm − µlm Lm
vm
knmn
kncm Lc −
Nm − µnm Nm
vm

krmr
Rm − µr Rb
vb
klml
=
Lm − µl Lb
vb
lnmn
=
Nm − µn Nb
vb
sp P
kcp (1 + kcpf Df + kcpp Dp )
=
+
(C − P ) − µp P
1 + (C + P )/p∞
vb
krcpf Df
klcpf Df
kncpf Df
Rc +
Lc +
Nc
vb
vb
vb
=

dDf
= τ1f Df (xf − Df )Sm − τ2f Df
dt
dDp
= τ1p Dp (xp − Dp )Sm − τ2p Dp
dt

(2.19)
(2.20)
(2.21)

(2.22)
(2.23)
(2.24)
(2.25)

(2.26)
(2.27)
(2.28)

(2.29)
(2.30)
(2.31)
(2.32)
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2.3

Results

2.3.1

Modeling Allogeneic Stem Cell Mobilization Using Filgrastim in
Normal Donors

The transients for a normal donor undergoing collection are given in Figure 3.
These transients are the result of the parameters given in Table 2 and Table 3. We see
that Filgrastim increases the levels of all cell types in the PB, but they stay within
biologically relevant ranges. The dynamics for cells in the BM that move directly
out into the blood. Differentiated cells are not shown in the figure. Their dynamics
are similar to those of the committed cells in the BM, with a different scaling. All
dynamics settle back down to steady state by day 20 of the simulations. Collection
of PSCs is occurring starting at day six and continuing through day nine. It is not
clear that anything is being removed in the transients because the removal process is
occurring at the same time as drug is being administered, and therefore the system is
quickly responding to the removal. With larger collection rate, which does not match
the data, collection is visible in the transients.
The drug response was fit such that stem cell collection yields cell numbers high
enough to be considered for transplantation. Normal donors typically yield adequate
CD34+ cell number for transplantation within three days, but patients tend to take
up to four or more days to yield enough cells. Therefore, we continue to simulate
for four days in order to allow for a baseline for collection that matches the required
number of days for diseased patients.
The collection dynamics can also be compared to data obtained in vivo, as shown
in Figure 4. The black ‘x’ indicates those donors that collected successfully over a
single day of collection. Data for collection each day was plotted for those that
collected two, three, and four days in green squares, red diamonds, and pink stars,
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Fig. 3. The transients corresponding to collection is shown for the non-diseased donor
model. Parameters used for this simulation are given in Table 2. Initial conditions are the steady state values given in Table 1. Filgrastim was given for
eight doses starting at day two.
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Fig. 4. Non-diseased donor data of collection numbers for one to four days of collection
are plotted. Black ‘x’s represent donors that collected in one day. Green, red,
and pink lines represent donors that collected in two, three, and four days,
respectively. The blue line is the mean of daily collection plotted as a single
donor. The blue bars indicate the standard deviation.
respectively. Data from the same patients are connected by appropriately colored
lines. The blue dots with bars show the mean and standard deviation of each day of
collection for all collections performed. The model results are plotted with the black
line and open circles . Given there is variability in the collection rates, the model
collects the same amount of cell each day.
We analyze the outcome of LHS from the non-disease donor model and classify
resulting patients as either poor or satisfactory collectors undergoing only Filgrastim
treatments. Out of a total of 1500 possible sets, 149 sets were considered biologically
acceptable to account for lymphoma. Table 4 outlines the results from the LHS by
identifying the mean, standard deviation, maximum, and minimum of the parameters
we altered. Of the 149 sets that were accepted, 84 collected a satisfactory number of
stem cells and 67 did not.
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5

4.5
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Fig. 5. The representative sets acquired from LHS of parameter space of the non-diseased donor fit are shown. The red (higher) curve shows accumulation of stem
cells using the parameters in the Satisfactory Collector column of Table 4, the
black (lower) curve shows accumulation of stem cells using parameters in the
Poor Collector column of Table 4, and the blue (middle) curve shows accumulation of stem cells using the non-diseased donor fit (starting) parameters. The
dashed line indicates the threshold for adequate stem cell collection.
Figure 5 shows the results of the simulations with the representative set for
satisfactory collection plotted in red, the representative set for poor collection plotted
in black, and the normal donor model fit plotted in blue. The dashed horizontal line
marks the point at which 420 million cells were collected, the threshold for satisfactory
collection for 72 kgs, which we assumed was the weight of all of normal donor and all
patients [8, 50, 51, 52].

In order to analyze the effect of parameter changes on biological steady state, we
mathematically determine which parameters are correlated with each other. sc and
kclc were the only pair that found to be significantly correlated. We plotted these
parameter versus each other and colored each point based on the amount of stem
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3.01
1.03×10−4

12.2

3.8

3.4

3.0

1×10−4

0.2

1.2
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collectors) and that do not collect well (poor collectors) are also shown.

and below the non-diseased donor fit. Representative sets of diseased patients that collect well (satisfactory

Table 4. The mean, standard deviation, minimum and maximum of the parameter sets obtained by sampling 15% above

0.0505

1.20

0.202

3.44

3.88

13.02

3.33

3.25

sc

Mean

Value

Parameter

Fit

Satisfactory Collection

cells collected, in Figure 6a. In this figure, satisfactory collectors are plotted with ‘x’
and poor collectors are plotted with ’o’.
Biologically relevant dynamics only arise when these parameters are directly
proportional. Given that there is no color pattern, we see that these parameters are
not driving collection numbers. Collection is dependent on the value of snc , which is
plotted in comparison to sc in Figure 6b. Higher value of the parameter snc correspond
to higher yield in stem cell collection.
2.3.2

Modeling Autologous Stem Cell Mobilization Using Filgrastim in
Patients

Next, we sample drug parameters 25% above and below both the satisfactory
and poor collection representative sets to for the drug parameters in the proliferation
and differentiation terms. Physiologically, it is expected that individual patients
may have a different response to the same drug, so this sampling allows us to show
this variability in populations. From the satisfactory representative set, out of 100
parameter samples, 24 became poor collectors. Similarly, from the poor representative
set, out of 100 parameter samples, 35 became satisfactory collectors. Table 5 outlines
the results of this sampling. The mean, standard deviation, minimum and maximum
of the resulting collections are given.
Figure 7 shows the collections numbers versus the parameter ksncf . This parameter has the most effect on collection results. This lead use to hypothesize when
the patient is on Filgrastim the most effective mechanism for increasing total stem
cells collected is by increasing the committed white blood cells moving into the periphery as CD34+ cells. As you increase the patients’ committed white blood cell
proliferation rate in response to the drug significantly increases collection numbers.
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Fig. 6. For each, parameter values are plotted with the point being marked by a color
based on the number of stem cells collected. For the top figure, points were
plotted at each (sc , sclc ) combination in the sampling and colored by their
collection totals. For the bottom figure, points were plotted at each (sc , snc )
combination in the sampling and colored by their collection totals. Satisfactory
and poor collectors are indicated by x’s and o’s, respectively.
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Collection Results

Mean

(total cells)

Standard

Minimum

Maximum

Deviation

Poor/Poor

378.9×106

22.6×106

336.6×106

418.1×106

Poor/Satisfactory

474.4×106

12.7×106

421.2×106

463.8×106

Satisfactory/Poor

402.5×106

11.5×106

385.6×106

419.8×106

Satisfactory/Satisfactory

474.4×106

31.8×106

420.9×106

530.8×106

Table 5. This table outlines the results of sampling drug parameter space. The first
two rows are associated with parameter sets created by sampling drug parameters kscf , ksncf , krcpf , klcpf , and kncpf . The last two rows correspond to
sampling over the same drug parameters, but with the satisfactory representative set. The mean, standard deviation, maximum and minimum values of
the resulting total cell collection are shown. The first label in column one
indicates which respresentative set was used for sampling. The second label
indicates the collection result after altering the response to Filgrastim. For
example, the second row displays the statistics for the parameter sets that
lead to satisfactory collectors, which were generated using the poor representative set.
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Total Stem Cells Collected (x103)
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Effect of k sncf and Collection Numbers
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Fig. 7. The effect of drug parameter ksncf on collection in the poor and satisfactory
case. Like before, satisfactory collectors are shown with ‘x’ and poor with ‘o’.
Points in black are from the sampling using satisfactory representative set and
points in blue used the poor collector representative set for sampling.
Following the sampling of drug parameter space to determine how responses to
the drug Filgrastim vary between patients, we include the use of Plerixafor for patients
that originally did not mobilize well enough for collection to be successful. We fit the
parameter that models the patients’ response to the level of Plerixafor in the body
such that all but the very worst poor collectors become satisfactory collectors, since
this drug is highly effective. Figure 8 shows the results for one poor collector before
and after Plerixafor treatment.

2.4

Discussion
We mathematically model the stem cell mobilization and collection process un-

der Filgrastim and Plerixafor drug treatment regimens. After fitting the model to the
normal case, we use statistical sampling to account for variability of underlying physiological dynamics in the model. The dependence of parameter values on biological
dynamics and response to the drug was also analyzed. We found that the parameter
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Fig. 8. This figure shows the results of Plerixafor salvage. Plerixafor in conjunction
with Filgrastim (solid line) increases the number of stem cells collected above
the threshold for collection. The long-dashed like is the accumulation of stem
cells before Plerixafor was used.
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kclc (the rate at which HSC differentiate into committed platelets) must be directly
proportional to sc (rate of self-renewal of HSC in the bone marrow) for the associated transients to be biologically relevant. The parameter snc (rate of self-renewal of
immune cell precursors in the bone marrow) was also found to be a driving force in
collection. If this parameter is not high enough, collection is typically not adequate.
In addition to analyzing the dynamics driving cellular interactions, representative
parameter sets that account for satisfactory and poor collectors are determined and
their parameters are used to analyze the response to Filgrastin. Specifically, we
use statistical sampling to vary the parameters associated with Filgrastin treatment
with both the satisfactory and the poor collector representative set. We analyze
the resulting parameter sets and transients and determined that the drug parameter
ksncf (increase of white blood cell replenishment due to Filgrastin) has the most effect
on collection numbers, a result which is biologically relevant. Collection was most
affected by changing snc and ksncf . Overall, Filgrastim presence on these processes
caused more committed white blood cells move into the periphery. We hypothesize
that the increase in this parameter cause a rise in CD34+ cells in the PB and thus,
collection is impacted positively.
Representative parameter sets that account for satisfactory and poor collectors
lead to a baseline over which to analyze variability in response to the drug Filgrastim in the system. Specifically, we account for variability in collection under drug
treatments by obtaining parameter sets using both a satisfactory and a poor collector
representative set. We determined that the drug parameter ksncf had the most effect on collection numbers, and we believe that this is due to the fact that committed
white blood cells move into the periphery when Filgrastim is present. We hypothesize
that the increase in this parameter cause a rise in CD34+ cells in the PB and thus,
collection is impacted positively. Following the sampling of Filgrastim drug affects
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on the dynamics, we analyze the inclusion of Plerixafor drug use in conjunction with
Filgrastim. Plerixafor rescue is a highly successful method for increasing collection
in patients that do not mobilize well, regardless of whether poor response to drug or
underlying disease dynamics are driving low collection.
Following the sampling of Filgrastim drug effects on the dynamics, we simulated
the inclusion of Plerixafor drug used in conjunction with Filgrastim. Plerixafor rescue
is a highly successful method for increasing collection in patients that do not mobilize
well. With this model we see that it is effective regardless of whether poor response
to drug or underlying disease dynamics are driving low collection.
Clinically, this model is useful in that it lends important quantitative insights
into the dynamics of HSC mobilization. Given that collection is driven by rate of
self-renewal of immune cell precursors, patients that do not mobilize adequate HSCs
for stem cell transplantation may have a lower rate of immune cell precursor selfrenewal. Also, the model indicated that background levels of these cell types are
normal in a patient, if the relationship between the rate at which HSC differentiate
into committed platelets and rate of self-renewal of HSC in the bone marrow are
linearly related. Therefore, if patients do not have normal background levels before
treatment, these rates may not be appropriately aligned. If this could be tested and
treated it may address underlying issues that could effect the ability for that patient
to collect.
Currently, we use a fixed rate of collection in order to focus on the how the
changes in the underlying dynamics drive changes in collection numbers. In order to
quantitatively match donor data the model would have to be altered to capture the
trend that collection numbers drop significantly following the first day of collection.
This base model gives insight into the driving dynamics of collection and if the first
step in finding a method to determine optimal drug protocols to increase collection
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numbers. Future work on this project would allow us to better capture the varying
day to day collection rather than focusing on overall collection numbers. Additionally,
we could adapt the model to account for stem cell loss in the periphery to organs and
then model the injection of stem cells back into the PB and analyze how well the
system returns to steady state. This would allow us to focus on effectiveness of the
stem cell transplantation rather than the collection.
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CHAPTER 3

MATHEMATICAL MODEL OF SYSTEMIC MEDIATORS IN THE
INFLAMMATORY PROCESS OF WOUND HEALING

3.1

Introduction
During the wound healing process, many cells and signaling molecules interact

to clean the wound site and repair the damaged tissue. When this process progresses
normally, an orderly inflammatory response removes the debris and pathogens and
allows the repair phase to begin and the wound to heal. However, trauma or diseases,
such as diabetes, can impair these cell interactions and signaling mechanisms. In
particular, an impaired inflammatory response can lead to chronic skin wounds, and
caring for chronic wounds is a challenging and very costly medical problem [53].
Prolonged wound healing requires extensive care, leads to patient suffering and high
health care costs, and affects more than six million people per year [54, 55]. The cost
to care for chronic skin wounds exceeds $25 billion per year in the US [53]. Even
in the absence of co-morbidities, wound healing does not always proceed normally.
In trauma patients with large wounds, complications can lead to sepsis, multi-organ
failure, and even death [56].
The body’s natural response to a wounding event involves four phases: hemostasis, inflammation, proliferation, and remodeling [57]. Understanding the interplay
between the four stages is essential to understanding the overall process. Because
many complications in wound healing are marked by unresolved inflammation, we
used mathematical modeling to analyze the dynamics of the inflammatory stage with
and without the effects of the systemic mediator estrogen. There is evidence that
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this hormone is highly involved in regulating inflammation, along with several other
components of the wound healing process [56, 9, 58, 59, 10, 60, 61, 62, 63, 64, 65, 11,
66, 67]. Initially, we model the dynamics of the inflammatory phase without other key
components of wound healing, in order to understand the role of different immune cell
populations. Following this study, the inflammatory phase model will be included in
a full wound healing model where the inflammatory, repair, and remodeling phases of
wound healing will be analyzed. The full model, including the effects of estrogen, is a
necessary step towards a model that accounts for gender that can be used to develop
new treatment strategies for patients with chronic wounds.
Estrogen receptors are present on many of the key cells involved in wound healing,
such as epidermal cells, neutrophils, and macrophages [59, 10, 11, 66]. Therefore,
estrogen can interact with the critical cells involved in the wound healing response,
and thus modulate the wound healing process. Overall, the absence of estrogen slows
healing [9, 10, 11]. Systemic effects of estrogen on the body are gender and age specific,
and therefore, the model with a non-zero estrogen parameter value represents a premenopausal female and the model with a zero estrogen parameter value represents
males and post-menopausal females.
Mathematical models of wound healing have been used to understand various
aspects of wound healing, including wound contraction, infection, diabetic complications, inflammatory response, and the role of oxygen in healing [68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84]. Wound healing is complex and
multiple mathematical techniques have been used to understand different aspects of
the process. Modeling approaches include the use of ordinary differential equation
(ODEs) [68, 69, 70], partial differential equation (PDEs) [72, 73, 74, 75, 76, 77, 78,
79, 80, 81, 82], and agent based modeling (ABM) [83, 84]. A review of modeling
efforts in the area of wound healing, [71], addresses the different aspects of wound
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healing and discusses the use of the modeling techniques relevant to the field. Most
models using PDE techniques analyze spatial wound dynamics, such as contraction
[75, 76, 79, 81] or angiogenesis and oxygen distribution [73, 74, 78, 82]. Because PDE
models are computationally expensive, these models do not focus on the complex
interactions between different inflammatory cells, nor do they consider the roles of
systemic mediators in the healing process.
In our previous work, Menke et al., we presented an ODE for the dynamics of
the inflammatory response and fibroblast activity and the resulting wound closure
rate is considered [69]. In general, we choose to work with an ODE model because
we are concerned with capturing the relative timing and strength of the various cells
and chemical signals during the phases of healing. The focus of this chapter is on
understanding when the entire inflammatory phase subsides and is not concerned with
the intra-wound complexities of the distribution of cells or the wound geometry. The
ODE modeling paradigm continues to be relevant for our work. Segal et al. extends
the Menke et al. model by accounting for the late stage deposition of collagen due
to fibroblast dynamics [70]. The new inflammatory phase model reported here is
the first to focus on the role of specific inflammatory cells, such as neutrophils and
macrophages, while accounting for systemic mediators.
3.2

Model Development
Neutrophils are the first responders of the inflammatory response and function

mainly by clearing debris and pathogens [54, 85, 86, 87]. Subsequently, activated
macrophages enter and continue to clear debris and pathogens, as well as clear apoptotic neutrophils that remain at the wound site. Once the wound is clean and the
neutrophil numbers have been reduced, the next stage of wound healing can begin
[88, 89].
39

In our previous models [70, 90, 91], the total inflammatory response is represented as a single variable. However, this is not detailed enough to model the
different roles the various inflammatory cells play during the healing process or the
different effects systemic mediators have on each type of inflammatory cell. Including
a separate variable for each cell population (macrophages and neutrophils) leads to a
more biologically accurate model. This is a necessary step in developing a model that
properly responds to changes in estrogen. Therefore, the equation for total inflammation from Segal et al. [70] is replaced with separate equations that model activated
macrophage (M ) and neutrophil (N ) activity. We also added a variable for the level
of debris in the wound (Pt ). Pathogen levels, represented by (P ) are modeled as in
Segal et al. [70]. The interactions between the variables in this inflammatory phase
model are depicted in Figure 9. The variables do not represent exact total cell counts
or concentrations. Instead, they are a relative measure of the populations activity.
Therefore, the variables are not fit to exact numerical values, but instead parameters are selected to qualitatively match the dynamics of the inflammatory phase of
normal healing. The models results will be validated by a comparison to experimental data for healing with neutrophils and macrophages individually blocked [92, 93].
Additionally, we altered terms to represent the effect of estrogen in the system and
compared our results qualitatively to published experimental data generated using
estrogen treated animals.
3.2.1

Pathogen Equation

In order to derive the new subsystem of equations we start with the variables P ,
N and M to represent pathogens, activated neutrophils and activated macrophages,
respectively. The pathogen equation, Equation (3.1), accounts for pathogen growth
and pathogen removal by both inflammatory cell types. The first term of the equation
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Fig. 9. Model schematic for the inflammatory response of wound healing. P , Pt , N
and M , represent Pathogen, debris consisting of Platelets, Neutrophils and
Macrophages, respectively. Arrows represent up-regulation and bars represent
destruction or inhibition.
represents the logistic growth of pathogen with carrying capacity, p∞ , and growth rate,
kpg . The second term represents the degradation of pathogen by the local background
immune response, such as antibodies. This term was derived by assuming that the
local response is in quasi-steady state. The parameters kpg , sb , µb , and kbp are the
rate constants for the local background immune response. Reynolds et al., 2006
provides additional details [90]. The final terms in the pathogen equation, −kpn P N
and −kpm P fi (M, N ), account for the phagocytosis of pathogen by each of the immune
cell populations [56, 92, 86, 87, 89, 93, 94, 95]. The inhibition on the second term is
added in order to account for neutrophil activity causing oxidation of the environment.
In turn this inhibits the ability of macrophages to clear pathogen [89, 96]. The
inhibition term has the form fi (x, N ) =

x
,
1+(N/N∞ )2

where the parameter N∞ controls

the level of N at which inhibition reduces macrophage activity by fifty percent. This
same inhibition function is used again when neutrophils limit the functionality of
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macrophages.
dP
= kpg P
dt
3.2.2



P
1−
p∞


−

kpb sb
− kpn P N − kpm P fi (M, N )
µb + kbp P

(3.1)

Debris Equation

The variable Pt accounts for signaling to the inflammatory cells due to the accumulation of debris at the wound site. When wounding occurs and blood vessels
are severed, the matrix is damaged and a large amount of debris is dumped into
the wound site. This debris includes red blood cells, white blood cells, degranulated
platelets, damaged extracellular matrix, bacteria, and foreign bodies. The debris
variable is named Pt due to the significant involvement of platelets in initiating the
inflammatory response, but all of these components of the debris are activators of the
inflammatory phase [85, 86]. Once the inflammatory cells are activated and recruited,
they remove the debris [54, 56, 92, 85, 86, 87, 93, 94, 95]. Neutrophils are typically
the first inflammatory cells to respond and they dominate this process [93]. In the
absence of neutrophils, macrophages are capable of removing the debris [89, 93, 95,
97]. The first two terms of the Pt equation, −kptn Pt and −kpm P fi (M, N ), model the
removal of debris by the inflammatory cells, see Equation (3.2). As in the pathogen
equation, macrophage removal of debris is inhibited by neutrophil activity.
dPt
= −kptn Pt N − kptm Pt fi (M, N ) + µN − µpt Pt
dt

(3.2)

The third term, µn N , represents the contribution of dying neutrophils to the
amount of debris present in the wound. Macrophages gradually exit the wound site
through the process of apoptosis and also exit via lymphatic drainage. Thus, they
leave very little debris behind [94]. The last term, −µpt Pt , accounts for the intrinsic
decay of signaling due to the removal of debris.
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3.2.3

Activated Macrophage Equation

To derive the macrophage equation, we first describe the behavior of resting fixed
tissue monocytes (MR ) and activated wound M1 macrophages (M ). We focus on the
inflammatory phase of wound healing, during which the main role of macrophages
is pro-inflammatory. Thus, our macrophage variable represents classical activated
macrophages, designated as M1 macrophages [98]. The basic reactions for the interaction between these variables are given in Table 6. It is assumed that when a resting
fixed tissue monocyte encounters either foreign material, a pro-inflammatory mediator (such as TNF), or a byproduct of neutrophil activity (such as reactive oxygen
species), it becomes activated [99]. This activation process occurs at a rate given by
R1 (Pt , P, M, N ) = kmpt Pt + kmp P + kmm M + kmn N . The first and second terms of
the R1 (Pt , P, M, N ) equation represents the activation of resting fixed tissue monocytes by the presence of debris and pathogen, respectively [86, 100]. The third term
of the equation represents the activation of resting fixed tissue monocytes by the
pro-inflammatory cytokines released by the activated macrophages [86, 95]. The final term accounts for the further activation of the resting fixed tissue monocytes by
neutrophils due to neutrophil byproducts [94, 100, 101, 102, 103].
When a resting fixed tissue monocyte encounters a protein or cell type capable
of activating it, it becomes an activated macrophage. These monocytes move from
the resting population to the activated macrophage population at the rate µmr , as
seen in Equation (3.3)-(3.4).
There is a natural source in the first equation to account for production of resting
fixed tissue monocytes from the bone marrow, the first term in Equation (3.3). The
final two reactions, indicated in Table 6, account for the intrinsic decay of both
macrophage populations, with a term included in each of the macrophage equations
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Reaction

Description

kmpt Pt +kmp P +kmm M +kmn N

MR −−−−−−−−−−−−−−−−−−→ M

Activation of resting fixed tissue monocytes (MR )
is induced by the presence of debris (Pt ) and
pathogen (P ), by positive feedback from the activated macrophages (M ) via pro-inflammatory cytokines and the harmful byproducts of neutrophils
(N ) function. The neutrophils associated activation is assumed to be nonlinear.

smr

∗ −−→ MR
µmr

MR −−→
µmr

M −−→

Source of MR
Intrinsic decay of MR
Intrinsic decay of M

Table 6. Reaction kinetics of the resting and activated macrophages. These interactions determine the activation of resting fixed tissue monocytes.
[104, 105].
dMR
= smr − µmr MR − R1 (Pt , P, M, N )MR
dt
dM
= R1 (Pt , P, M, N )MR − µM M
dt

(3.3)
(3.4)

Since the activation process of resting fixed tissue monocytes (MR ) is rapid once
it begins, we can assume that the variable MR is in quasi-steady state and reduce
Equations (3.3)-(3.4) to a single activated macrophage equation, Equation (3.5) [94].
For the remainder of this work, we refer to “activated macrophage(s)” as simply
“macrophage(s).”
dM
smr R1 (Pt , P, M, N )
=
− µm M
dt
µmr + R1 (Pt , P, M, N )
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(3.5)

3.2.4

Activated Neutrophil Equation

The derivation of the neutrophil equation follows the same process as the macrophage
equation. However, the activation term is developed for neutrophils by assuming that
debris and pathogen are the only activators of neutrophils [56, 85],[86]. Therefore,
the rate of activation is R2 (Pt , P ) = knpt Pt + knp P . We again use a quasi-steady state
assumption on the resting population to form the activation term for the activated
neutrophil equation, Equation (3.6).
Macrophages present at the wound site actively remove the neutrophils that are
laden with bacterial and debris and have moved into a state of apoptosis [54, 106]. The
term −kptm Pt fi (M, N ) is added to the neutrophil equation to model this interaction.
Again, the adverse environment of a wound with high neutrophil activity inhibits the
macrophage activity in the wound and therefore, we add inhibition to this term. The
final term in Equation (3.6) accounts for the intrinsic decay of activated neutrophils.
snr R2 (Pt , P )
dN
=
− knm fi (M, N ) − µn N
dt
µnr + R2 (Pt , P )

3.3

(3.6)

Modeling the Effect of the Systemic Mediator Estrogen on Inflammation
To account for estrogens effect on the inflammatory process, we introduced an

estrogen parameter, E, with E = 0 representing no estrogen and E = 1 representing
normal estrogen. A well accepted characteristic of neutrophils is that they stick to
the walls of blood vessels surrounding the wound site and move through the vessels
into the wound [56]. When estrogen is present the infiltration of neutrophils into
the wound site decreases [9, 59]. In the first term of Equation (3.6), we account

45

for the activation of resting neutrophils and determine the level neutrophil activity
in the wound. By inhibiting this term, we effectively inhibit the total activated
neutrophil activity in the wound. We use the same form of inhibition as we did with
neutrophil inhibition of macrophages, by using the function fEN (x, E) =

x
.
1+(E/EN ∞ )2

The parameter EN ∞ controls the level of estrogen that gives rise to a fifty percent
reduction in activation (and influx). The other terms in the neutrophil equation are
unchanged by estrogen, so the neutrophil equation becomes Equation (3.7).
dN
= fEN
dt



snr R2 (Pt , P )
,E
µnr + R2 (Pt , P )


− µn N − knm N fi (M, N )

(3.7)

There is also evidence that estrogen increases the phagocytic ability of neutrophils and macrophages [9, 59]. Therefore, we add a multiplier to all phagocytosis terms in the pathogen and debris equations, Equations (3.8)-(3.9), respectively.
This multiplier is set to one when estrogen is off and greater than one when estrogen is on. The pathogen phagocytosis terms become −kpn P N (1 + ken E) and
−kpm P fi (M, N )(1 + kem E). The parameters ken and kem control the relative effect of estrogen on neutrophils and macrophages, respectively. Similarly, the phagocytosis terms for debris are also modulated by estrogen, −kptn Pt N (1 + ken E) and
−kptm Pt fi (M, N )(1 + kem E) . The updated equations for pathogen and debris are
Equations (3.8) and (3.9), respectively.
dP
= kpg P
dt



P
kpb sb P
1−
−
− kpn P N (1 + ken E)
p∞
µb + kbp P

(3.8)

− kpm P fi (M, N )(1 + kem E)
dPt
= −kptn Pt N (1 + ken N ) − kptm Pt fi (M, N )(1 + kem E) + µn N − µpt Pt
dt

(3.9)

There is also evidence that estrogen inhibits the differentiation rate of fixed tissue
monocytes into activated M1 macrophages that clear the wound following neutrophil
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infiltration [9]. More specifically, the presence of estrogen down-regulates the effectiveness of macrophage recruitment of additional macrophages. While this may
seem detrimental to wound healing, it is acting as a mediator to the inflammatory
response, and therefore decreases the likelihood that a wound will enter into a stage
of chronic inflammation (6). The rate constant for macrophage activation by its own
cytokines becomes fEM (kmm , E) =

kmm
,
1+(E/EM ∞ )2

where EM ∞ plays the same role for

macrophages as EN ∞ does for neutrophils. These parameters are not set to be equal
because, as with ken and kem , we do not assume that estrogen affects neutrophils and
macrophages equally. The equation for macrophages with estrogen inhibition is given
in Equation (3.10)
dM
sm R1 (Pt , P, N, M )
− µm M
=
dt
µmr + R1 (Pt , P, N, M )

(3.10)

with R1 (Pt , P, N, M ) = kmpt Pt + kmp P + fEM (kmm , E)M + kmn N .
3.4

Final Equation
The full model that includes the effects of estrogen gives the final form of our

equations, Equations (3.11)-(3.14). The code for this system are given in Appendix
B.
dP
= kpg P
dt



P
1−
p∞


−

kpb sb P
− kpn P N (1 + ken E)
µb + kbp P

(3.11)

− kpm P fi (M, N )(1 + kem E)
dPt
= −kptn Pt N (1 + ken N ) − kptm Pt fi (M, N )(1 + kem E) + µn N − µpt Pt
dt


dN
snr R2 (Pt , P )
= fEN
, E − µn N − knm N fi (M, N )
dt
µnr + R2 (Pt , P )
dM
sm R1 (Pt , P, N, M )
=
− µm M
dt
µmr + R1 (Pt , P, N, M )
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(3.12)
(3.13)
(3.14)

with the rate equations R1 (Pt , P, N, M ) = kmpt Pt + kmp P + fEM (kmm , E)M + kmn N
and R2 (Pt , P ) = knpt Pt + knp P and the inhibition functions fEN (x, E) =
and fEM (kmm , E) =
3.5

x
1+(E/EN ∞ )2

kmm
.
1+(E/EM ∞ )2

Initial Conditions
Immediately following wounding, blood floods into wound site and brings in

circulating red blood cells, neutrophils, and platelets. The trauma that created the
wound, unless surgical, will introduce pathogens to the wound site. Therefore, the
initial conditions for all wounds have nonzero neutrophils (N ), debris (platelets and
clot) (Pt ) and pathogens (P ) [85, 86]. The initial value of the debris and pathogen
variables will indicate the severity of the wound. Because neutrophils originate in the
blood, and the concentration in the blood is independent of the wounding event, they
are always set to the same level initially [107]. We use Pt = 2, P = 0.1, N = 0.1, and
M = 0 as the standard wound initialization.
3.6

Parameter Estimation
During normal healing there are various phenomenon that occur: neutrophil

activity peaks between day one and two [56, 92, 86, 89, 93] and macrophage activity
peaks between days three and five [108]. Given that these dynamics hold for various
patients who likely do not have the same underlying immune response rates, we did
not seek a single parameter set to satisfy these conditions but rather a collection of
sets that satisfy conditions for both the parameters and their associated transients.
First, we select parameter sets that satisfied the conditions for a stable fixed
point corresponding to health, (Pt , P, N, M ) = (0, 0, 0, 0). Note that while the initial
condition for N is nonzero due to influx from the blood during injury, in the healthy
state N is zero since neutrophil activity locally resolves to its pre-injury level. Lin48

Parameter Name
kpg
p∞
kbp
sb
µb
kpb

Description

Value

Pathogen growth rate
Carrying capacity of the pathogen population
Activation of local background immune response by pathogen
Source of background local response
Intrinsic decay of local response
Destruction of pathogen by local background response

14.4/days
20 (106 /cm3 )
0.2/days/P-units
0.12 M-units/days
0.048/days
14.4/M-units/days

Table 7. The model parameters for the local background immune response are given.
These parameters were unchanged during the parameter space sampling.
These parameters were set to their values from [Rey2006]
earization of equations about the health fixed point yield parameter conditions for
which the fixed point is stable:
1) kpg <

kpb sb
,
µb

2) kmm <

µm µmr
,
smr

and 3) knpt <

µpt µnr
.
snr

Our focus is on a wound started via an increase in debris and not due to a
pathogen insult. Also, because of the minimal role that the background local response plays in the general dynamics, the parameters associated with the background
response in this inflammatory phase model are held fixed at their values from the original inflammation model, Reynolds et al. [90], see Table 2. The first condition for
health is satisfied with the parameters fixed at these levels.

Latin Hypercube Sampling is then used to determine most of the remaining parameters. One parameter value from each of conditions (2) and (3) for stable health,
kmm and knpt , respectively, are not determined using Latin Hypercube Sampling.
Instead, they are sampled from a uniform distribution such that the associated conditions are satisfied. To determine the value for kmm , we first find µm , µmr , and smr
for each parameter set and then use their ratio from the second condition to determine
the maximum for kmm over each parameter set. The parameter kmm is then selected
from a uniform distribution with this value as the maximum. The same process is
completed to determine knpt .
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Additionally, parameters that have known biological values or constraints are
selected to satisfy those conditions, see Table 3. Also, we enforce a range on N∞
that is determined by the source and decay rate of neutrophils. This is implemented
to ensure that the strength of the inhibition by neutrophils is appropriate. During
our initial sampling, we used the same minimum and maximum for all parameters
that we do not put restriction on, but we were not successful at finding a significant
number of sets. We used the sets we did find to refine the maximums and minimums
to the values in the table. If no minimum is explicitly stated we use 0.0001.
Our sampling is performed using the Latin Hypercube Sampling method developed by Marino et al. [47]. Parameter space sampling is used to formulate a set of
feasible parameter values, each set is then used in a model simulation with the initial
conditions stated above and accepted if it satisfies the following conditions:
1) The peak for neutrophils was between 0.75-2.75 days [56, 92, 86, 89, 93],
2) The peak for macrophages was between 2.75 -6.25 days [108], and
3) Macrophage levels dropped below 0.1 by day 20.
The ranges on the peak times are broader than those stated in the literature.
This is for two reasons: First, experimental data is not collected frequently enough
to determine exact thresholds on these ranges, so we extend them in both directions.
Second, the repair phase and the anti-inflammatory mediators triggered during the
inflammatory stage are not modeled in this subsystem. To account for this lack
inhibition we lengthen the range by accepting sets with later peaks. The final check
on macrophage activity levels is to ensure that the resulting transient resolved to
the healthy fixed point in a timely manner. Overall these conditions produce 1369
acceptable sets out of a sample of 100,000 possible sets.
In our previous models, estrogen was not explicitly modeled, but calibration
and validation was based on published data for normal healing in experiments using
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female animals [69, 70]. Therefore, to determine values for the estrogen parameters
we perform a similar process as before, but we turn estrogen off and accepted sets
only if the resulting transient changes appropriately. We test this estrogen parameter
estimation method with various sets from the initial 1369 sets determined from the
normal dynamics and note similar changes in transients when estrogen is removed.
However, to determine the final set of acceptable estrogen parameters we focus on
one representative parameter set from the 1369 parameters sets we found for normal
healing to determine the estrogen parameters.
We cannot use the mean of the 1369 parameter sets as the representative set
since it does not satisfy the conditions for health. Instead, we determine the average
behavior of each variable versus time, which we refer to as the mean of the transients. We then choose a parameter set that minimizes the Euclidean norm between
its associated transients and the mean of the transients, and we refer to it as the representative parameter set. This set is used when determining the estrogen parameter
sets.
It is documented that the influx of neutrophils decreases slightly when estrogen is
present [9, 59], but there is not sufficient understanding for the changes in macrophage
activity in the presence of estrogen to implement a condition on the macrophage
transients. Therefore, we set our condition for acceptable sets as those that give rise
to increase of 5-15% in the peak of neutrophils when estrogen is removed and the
conditions for a stable healthy fixed point are still satisfied. The range of 0.0001
to 10 is used on all estrogen parameters during sampling. Sets are accepted if their
associated transients change such that the peak of the neutrophils decreases by 5-15%
[63].
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3.7

Results
This inflammatory phase model of wound healing consists of a fixed set of equa-

tions with a collection of 1369 acceptable parameters sets. Below, we describe the
behavior of this model. Finally, we investigate the behavior of the model in response
to estrogen and cortisol.
3.7.1

Pt /P /N /M System without Systemic Mediators

The transients of the inflammatory equations of the Pt /P /N /M system behave
similarly to the transient of the inflammatory equation in Reynolds et al. [90] and
satisfy the conditions set for parameter fitting. Figure 10 shows sample transients
from the normal healing sets with estrogen present (E = 1). Given that most of
the pathogen-associated parameters are fixed, there is very little variability in the
pathogen transients.
Figure 11 illustrates the main differences in the representative sets transients
and the mean of transients found by averaging over the transients associated with all
1369 sets. The neutrophils transient for the representative set is similar in shape to
the mean of the transients, but with a slightly lower peak neutrophil level. However,
the macrophage transient from the representative sets peaks later than the mean of
the transients with a slightly higher macrophage level at the peak. The mean of the
transients also has a longer tail. The differences between P and Pt were minimal.
The values of the parameters in the representative set and the statistics from the
acceptable parameter sets are given in Table 8. Additionally, the conditions used for
fitting each parameter are also given in this table.

Peak time data is calculated from transients associated with each acceptable
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Destruction of pathogen by
neutrophils
Destruction of pathogen by
macrophages
Controls neutrophil inhibition
Destruction of debris by neutrophils
Destruction of debris by
macrophages
Intrinsic decay of debris
Activation of neutrophils by
pathogen
Activation of neutrophils by
debris
Source of neutrophils
Decay rate of resting neutrophils
Decay rate of activated neutrophils
Destruction of neutrophils by
macrophages
Activation of macrophages by
pathogen
Activation of macrophages by
their associated cytokines
Activation of macrophages by
neutrophil byproducts
Activation of macrophages by
debris
Source of resting macrophages
Decay
rate
of
resting
macrophages
Decay
rate
of activated
macrophages

Description

<4

< N∞ <

snr
µnr

µnr µpt
snr

µm µmr
smr

0.2 < µm < µn

0.22 < µmr < 0.693

0.1 < smr < snr

< 100

< 80

kmm <

< 40

<8

0.96 < µn < 1.44

2.304 < µnr < 3.456

0.15 < snr < 2

0.15 < knpt <

< 40

< 0.5

< 30 3.16/M -Units/day

snr
4µnr

< 40 34.80/M -Units/day

< 40

Conditions

49.91
0.22
0.46
0.71

41.5/Pt -Units/day
0.17M -Units/day
0.54/day
0.50/day

19.85

18.52/P -Units/day

40.30

3.12

6.42/M -Units/day

10.58/N -Units/day

1.13

1.02/day

0.88

2.94

0.06/M -Units/day

0.38

19.31

0.58

0.38

17.58/Pt -Units/day

3.30/day

8.00

11.17
0.37/day

2.15

1.53

2.03/N -Units/day

2.97/Pt -Units/day

0.10

11.57

19.91
0.11/N -Units

20.38

Mean

35.03/N -Units/day

Representative
Set

0.27

0.14

0.12

28.78

23.20

0.84

11.87

2.29

0.96

0.33

0.15

1.39

11.47

0.084

0.031

1.08

0.089

0.0014

11.61

Standard
Deviation

0.20

0.22

0.10

0.14

0.075

0.00056

0.003

0.004

1.44

2.304

1.99

0.18

0.039

0.13

29.96

0.0016

0.013

39.95

0.022

Minimum

1.41

0.692

1.07

99.98

79.97

5.71

39.99

7.99

[107]

2.456

10.45

39.97

0.5

3.99

0.72

39.99

Maximum

indicates a parameter chose such that one of the conditions for a stable fixed point representing health was
satisfied.

deviation, maxiumu, and minimum from the 1369 normal healing acceptable sets (with estrogen (E = 1)). HS

for estrogen sampling. Mean, Standard deviation, Maximum, and Minimum columns are the mean, standard

Table 8. The parameter set data in which conditions were satisfied during sampling. Representative set values were used

µm

µmr

smr

kmpt

kmn

kmm

kmp

knm

µn

µnr

snr

knpt

knp

µpt

kptm

kptn

N∞

kpm

kpn

Parameter
Set

[109]

[47]

[108]

HS

[107]

HS

[64]

Ref

Fig. 10. Sample transients of the inflammatory subsystem are shown. The sets used to
create these transients were randomly selected from the 1369 sets found using
normal conditions (E = 1), with initial conditions Pt = 2, P = 0.1, N = 0.1,
and M = 0.

Fig. 11. A comparison of the mean of transients and the representative set is shown.
The mean of the transients for neutrophils and macrophages are plotted in
blue. The transient from the representative set are plotted in black (dashed).
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Data
Set
Normal Condition
Transients
“Representative”
parameter set
No Macrophage
Experiment
No Neutrophil
Experiment

Populations

Mean
(days)

Minimum
(days)

Maximum
(days)

Standard
Deviation
(days)

Macrophages

4.08

2.77

6.21

0.80

Neutrophils

0.91

0.75

1.69

0.13

Macrophages

4.37

-

-

-

Neutrophils

0.88

-

-

-

Neutrophils

1.22

0.8

2.76

0.25

Macrophages

2.82

1.41

5.32

0.67

Table 9. Peak time for the normal condition of the wound healing model is shown
to validate the experiments. The mean, maximum, minimum, and standard
deviation of the transients of all final parameter sets from the normal conditions simulations (E = 1), Representative set (column 4 of table 6), no
macrophage experiments (smr = 0), and no neutrophils experiments (snr = 0
and N (0) = 0).
parameter set, see Table 9. Though the parameter estimation allows for peaks time
ranging from 0.75-2.25 days for neutrophils, the acceptable sets have a narrower range,
0.75-1.69 days. The range for the macrophage peak is the same as the selection
condition. This is a validation of the resulting sets because neutrophil activity is
resolved before the anti-inflammatory effects associated with repair are significant.
Therefore, macrophages alone should be able to modulate the neutrophil activity
during normal healing. Additionally, anti-inflammation mediators will be needed to
achieve the normal dynamics for the macrophage population. For the representative
set, the peak occurs within one standard deviation of the peak of transients.

We determine the correlation coefficient for each pair of parameters that are
varied. In general, there is not a strong correlation between parameters. Only two
parameter pairs have correlation coefficients greater than 0.5. The correlation coefficient for snr and N∞ is 0.80 and snr and knpt was −0.67. Figure 12 shows the
relationship between these parameter pairs. The plot on the left shows the positive
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Fig. 12. Accepted parameter sets are shown and colored by the maximum neutrophil
level. The plot on the left has a point plotted as (snr , N∞ ) for each of the
1369 accepted parameters. The points are colored by the value of N a its peak
for that particular set. The point on the right is the same, but with points
plotted as (snr , knpt ).
correlation between snr and N∞ . This plot has a point plotted at (snr , N∞ ) for each
of the 1369 accepted parameters. The points are colored by the value of N at its peak
for that particular set. The right plot shows the inverse relationship between snr and
knpt , using points plotted at (knpt , snr ). Most of the sets have peak values in the lower
range (0.1-0.2, blue-light green). The peak value color pattern in more structured in
the plot on the right, indicating a stronger dependence of the peak value on the value
of knpt than N∞ .
The relationship between these pairs is not surprising given that the conditions
used to determine and knpt depended on snr . What is unexpected is that the other
parameters involved in these conditions are not correlated. For example, even though
µn also controls N∞ , it is not significantly correlated with N∞ . Also, no parameters
involved in the second condition for the stability of health or affecting macrophages
directly are significantly correlated with each other.
To further validate the model, we consider our inflammatory phase model with
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Fig. 13. The resulting transients of validation of the model by removal of macrophages
(top) and removal of neutrophils (bottom) are shown. For each, the black,
dashed curve is the representative transient with normal parameters and the
blue curve is the resulting transient when an immune cell population was
removed. The no macrophage data was obtained from [92]. The no neutrophil
data was obtained from [93] and is calculated from cell counts at 24 hours.
both neutrophils and macrophages removed. None of the methods used for the parameter estimation considered these scenarios, but the model is still able to capture
these dynamics. When macrophages are removed, it has been shown that there is
little change in the peak of neutrophils, but there is delay in resolution for neutrophils
[92]. When neutrophils are removed, macrophage population peaks slightly higher at
a later time, but with no difference in population at 24 hours.

Figure 13 (top) shows how the removal of macrophages affects neutrophils in the
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model and in similar experiments. The black dashed line is the normal response using
the representative parameter set and the blue line is the neutrophil transient when
macrophages are removed (smr = 0). The time course of the response is prolonged
and neutrophil numbers are elevated, which qualitatively matches the experimental
results from Leibovich and Ross [92], top right of Figure 13.
Figure 13 (bottom) shows how the removal of neutrophils affects macrophages.
Again the black dashed curve is the transient from the representative set and the
blue is the resulting transient when neutrophils are removed. The dynamics of the
macrophages are unaffected by the removal neutrophils for about the first 3.5 days
and then the peak of the macrophages is at a slightly higher level and delayed, but
qualitatively the same. This matches the data from Simpson and Ross [93], which
shows no significant difference of macrophages at 24 hours. Although they do not
provide transient data for cell counts in the wound, they do state that the number of
monocytes and their phagocytic activity appeared to be the same in the control and
neutropenic wounds [93].
The removal of macrophages and neutrophils is simulated in all of the 1369
acceptable sets. The changes in the peak times and ranges of the remaining cell
population are given in Table 10. When macrophages are removed, the mean peak
time for neutrophil activity is delayed by 0.31 days and the range is extended. The
minimum remains nearly the same, but the maximum peak time in the population is
delayed by 1.07 days. Macrophage activity peaks early in the absence of neutrophils.
The mean peak time, minimum peak time and maximum time are all earlier by 1.26,
1.36 and 0.89 days, respectively.
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3.7.2

Effects of the Systemic Mediator Estrogen

When Latin Hypercube Sampling of parameter space is performed for each of
the parameters associated with estrogen, we assume that the representative set corresponds to experiments with estrogen on (E = 1). In order to simulate the no
estrogen case we adjust the parameters affected by estrogen and then simulate the
model with E = 0. For example, in the representative set kpn has the value 35.03
per N -units/day. We assume this is the rate at which pathogens are destroyed by
neutrophils when estrogen is present, therefore when we model estrogen explicitly and
set E = 1. During sampling, we determine a collection of ken and the other estrogen
parameters, which all give rise to the correct dynamics when estrogen is removed.
This means that ken is set to a value and we solve for kpn . For example, if ken = 2 for
a particular set, then kpn = 11.58 for that set. We do similar calculations for all other
parameters in estrogen effected terms and run our model with these parameters and
E = 0 to determine the no estrogen transients for that particular set.
Using this method and accepting sets that have an increase of the peak on neutrophil activity of at least 5% and at most 15% we collected 1,170 acceptable parameter sets. The only notable structural constraints in the resulting distributions for the
estrogen parameters are on the EN ∞ distribution. EN ∞ ranges between 3.78 and 10,
though sampling allows EN ∞ to range between 0.0001 and 10. All other parameters
fill the allowable range used to determine them. Overall statistics for the estrogen
parameters are given in Table 10.
In order to analyze the effect of each parameter on the peak of neutrophils, we
plot points at (ken , EN ∞ ) and color them by the percent increase in the neutrophil
peak when estrogen is removed, Figure 14 (left). This compares the effect of estrogen
on the ability of neutrophils to phagocytize pathogen with its effect on the inhibition
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Parameter Name

EN ∞

ken

EM ∞

kem

Description
Controsl
estrogen
inhibition of
activation and
influx
Controls
estrogen
increase in the
phagocytic
abilities of
neutrophils
Controls
estrogen
inhibition of
self-activation
by
macrophages
Controls
estrogen
increase in the
phagocytic
abilities of
macrophages

Mean

Std Dev

Minimum

Maximum

References

6.80E-Units

1.79

3.78

10

[56]

5.37/E-Units

2.74

0.002

10

[58, 59]

5.00E-Units

2.94

0.004

10

[58, 67]

4.97/E-Units

2.90

0.002

10

[58, 10]

Table 10. Description of the estrogen parameters, mean, standard deviation, minimum, and maximum for resulting sets. The sampling of each parameter is
constrained so that that value is set less than ten.
of the activation of neutrophils. As EN ∞ is increased, inhibition by estrogen on
the activation of neutrophils is decreased. Therefore, when estrogen is removed the
change in the peak is less for larger EN ∞ . As ken is increased, estrogen facilitates
neutrophils phagocytosis more effectively. So when estrogen is removed, the peak
of the neutrophil activity increases as ken increases. The changes in the neutrophil
activity peak are more sensitive to changes in these parameters in the strong inhibition
(EN ∞ smaller) and smaller facilitation (ken smaller) region. In the higher ken region
the change in peak levels is mostly due to change in the inhibition parameter.
On the right plot of Figure 14, we plot points at (kem ,EM ∞ ) and color them
by the percent increase in the macrophage peak when estrogen is removed. This
allows us to compare the effect of estrogen on ability to facilitate the phagocytosis
of macrophages to its inhibitory effect on the ability of macrophages to self-activate.
Like with the neutrophil associated parameters, as EM ∞ is increased, inhibition by
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Fig. 14. The results of estrogen parameters contribution to the percent change in peak
time of neutrophils (left) and macrophages (right) are shown. On the right,
points were plotted at (ken , EN ∞ ) and colored by percent increase in the peak
of neutrophil activity when estrogen is removed. On the left, points were
plotted at (kem , EM ∞ ) and colored by the percent increase in the peak of the
macrophage activity when estrogen is removed.
estrogen on the macrophage self-activation is decreased. However, changes in this
parameter do not significantly affect the peak of macrophages. As kem is increased,
estrogen facilitates macrophage phagocytosis more effectively. So when estrogen is
removed the peak of the macrophage activity increases as kem increases.

To investigate the change in the overall transients as a result of removing estrogen
from the system, we plot the mean of the transient with no estrogen, the transients
from the representative set, and indicate the region contain all no estrogen transients
(gray regions) in Figure 15. The solid line indicates transients of debris and the
inflammatory cell populations from the representative set (with estrogen on, E = 1).
The dashed line is the mean of the resulting set of transients with estrogen removed
(E = 0). As expected, the absence of estrogen increases the peak of neutrophils
and delays the peak, causing a slightly extended inflammatory response. As for
macrophages, there is a significant delay in resolution, if the macrophages return to
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Fig. 15. The change in the transients due to the removal of estrogen is shown. Transients from the representative set (estrogen on, E = 1) are plotted in black
(solid curve) for debris (left), neutrophils (center), and macrophages (right).
The dashed line is the mean of the transients that resulted from removing
estrogen (E = 0). All resulting sets with E = 0 lie in the gray region. For the
macrophage plot, the darker gray region indicates where most of the resulting
transients lie.
zero. The darker grey band contains most of the transients and those in this band
resolve to the healthy outcome, indicating that a majority of parameter sets lead to
transients that resolve to zero macrophages. The light band contains a few transients
and these lead to unhealthy, inflamed outcome with elevated macrophages. This is due
to the fact that our standard initial conditions are no longer in the basin of attraction
of the healthy outcome. These changes in the inflammatory cell population can give
rise to either faster or delayed removal of debris. The overall effect of removing
estrogen does not change the pathogen transients significantly (not shown).

3.8

Discussion
We derive a model focused on neutrophils and macrophages, the two major cells

types in the inflammatory response during wound healing. Furthermore, this model
accounts for the inclusion of systemic mediators cortisol and estrogen in order to better
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capture the dynamics of the wound healing process. Latin Hypercube Sampling of
parameter space is performed, first on the system without any mediators, and then
individually on the system with the each systemic mediators to determine acceptable
parameter sets for known biological phenomenon.
Latin Hypercube Sampling of parameter spaces for this expanded inflammatory
system is successful at choosing sets of parameters that yield appropriate dynamics
based on the different roles of the different inflammatory cell types. This collection of
parameter sets is representative of a population of individuals with slight differences
in normal wound healing dynamics. This lays the groundwork to establish a patient
specific model of wound healing to predict patient outcome and to provide patient
specific treatment protocols.
In order to create a model that more accurately accounts for differing dynamics with the normal population, the inclusion of systemic mediators is necessary.
Specifically, the inclusion of estrogen in the system allows for gender- and age-based
models that more accurately account the differences in healing of pre-menopausal
females versus males and older females. It is known that the presence of estrogen in
pre-menopausal females leads to a more effective healing response than in males and
post-menopausal females [58, 10, 11] and our model accurately captures this behavior.
The sampling process focuses on changes in the peaks of the inflammatory response, but is able to capture many aspects of wound healing process. Simulations of
the inflammatory model without systemic mediators using each parameter set shows
that appropriate dynamics are achieved for each of the inflammatory populations for
the entire set of parameters. Additionally, the model is validated by removing each of
the inflammatory cell populations and comparing these results to experimental data.
Without macrophages, the neutrophil response is lengthened, but pathogen and debris are cleared. Without neutrophils, the macrophage response is more effective and
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shortened due to the lack of oxidative stress caused by neutrophil activity.
Simulations of the model with estrogen on the accepted sets lead to biologically
accurate transients. In the presence of estrogen, neutrophil infiltration and fixed tissue
monocyte differentiation into active macrophages is inhibited [56, 58]. This causes
macrophage response to occur sooner with estrogen on than in those wounds without
estrogen and thus leads to a more effective inflammatory response when estrogen is
present. Also, the phagocytic ability of neutrophils and macrophages is increased
when estrogen is presence, which also contributes to a more effective inflammatory
response to remove pathogens and debris [9, 59].
Our results illustrate that Latin Hypercube Sampling of parameter space is successful at capturing these biological dynamics and can be used to account for variation
in population. It remains for the model to be incorporated in the larger model for
wound healing, which includes fibroblast infiltration and collagen deposition and maturation. Additionally, the regulation of wound healing by macrophages that occurs
during the repair phase, and is a hallmark of the M2 type macrophages, will need to
be accounted for in the full model. We anticipate that the full model will allow us
to explore wound dynamics in the population under circumstances of trauma with
differing levels of estrogen based on gender and age. Additionally, a detailed model of
the inflammatory phase allows for future implementation of new treatment strategies
that modulate the inflammatory process. This will be a necessary step to studying
effective treatments of chronic wounds. Chronic wounds typically result from a failure
to resolve the prolonged inflammatory phase of healing and therefore treating these
wounds requires an understanding of both macrophage and neutrophil activity.
1
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CHAPTER 4

MATHEMATICAL MODEL OF GAS EXCHANGE IN THE LUNGS
AND BODY

4.1

Introduction
Ventilation induced lung injury (VILI) is a substantial medical issue that harms

patients and challenges physicians. Damage from VILI causes fluid to accumulate in
the capillaries of the lung causing acute respiratory distress syndrome (ARDS), which
makes oxygenation of the surrounding lung tissue difficult and oftentimes impossible
and can cascade into lack of oxygenation of tissues throughout the body. This damage
is exacerbated in elderly patients, who tend to have other diseases and damage to
their lungs when treatment is required. In 2005, 8 thousand hospitalizations required
mechanical ventilation, 4% of which were elderly, high risk patients, and 45% of which
had addition medical conditions [110]. Mathematical modeling of lung ventilation
could aid physicians in making a priori decisions about the need for ventilation in highrisk patients and save lives. In this chapter, we will discuss the biological background
of the breathing cycle and oxygenation of tissues in the lungs and body and we will
introduce and analyze a modified mathematical model of gas exchange and other
processes involved in the oxygenation.
4.1.1

Biological background

In the lung, a tissue barrier lines the alveolus and separates blood in the capillary
from the air in the alveolus. Oxygen molecules diffuse, or move from an area of high
concentration (the airspace) to an area of lower concentration (the blood in the lung
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capillary). On the otherhand, this tissue in the body requires oxygenation. So when
blood flows near a low-oxygenated tissue, the oxygen molecules diffuse from the blood
into the tissue. Hemoglobin molecules present in the blood of the capillaries bind
oxygen molecules and transport it out of the lungs and into the body. In the body,
the oxygen unbinds from the hemoglobin and diffuses out into the surrounding tissue.
Hemoglobin and oxygen cooperatively bind, which is facilitated by four heme
groups onto which the oxygen attaches.

Oxygen-rich hemoglobin, called oxyhe-

moglobin, is classified as unsaturated if all heme groups are lacking oxygen, partially
saturated if one to three heme groups are oxygenated, and fully saturated if all four
heme groups are oxygenated. Each time an oxygen molecule binds to one of the heme
groups, the shape of the molecules chages and its affinity for subsequent binding is
reduced.
Alongside the exchange of oxygen in the capillaries of the body, carbon dioxide
dynamics are occurring at the same time and in the direction opposite relative to
oxygen. In the peripheral body, carbon dioxide diffuses into the blood from the tissue
where it is carried into the lung diffuses from the capillary blood through the tissue
barrier and into the alveolus of the lung. It is subsequently expelled on exhalation.
The presence of water molecules in the blood facilitates the creation of a carbonic
acid molecule, which dissolves in the blood. This dissociation creates a bicarbonate
ion and a hydroxide ion, which can be used to calculate the pH of the blood at a
given location in the body. An increase in the amount carbon dioxide makes the
blood more acidic and a decrease in the amount of carbon dioxide makes the blood
more basic. Thus, changing levels of carbon dioxide in the blood causes changes in
pH of the blood which also affects the dissociation of oxygen, and therefore affects
hemoglobin’s affinity for oxygen. An increase in pH (making the blood more basic)
makes hemoglobin’s affinity for oxygen increase, and a decrease in pH (making the
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Fig. 16. This figure shows graphical representation of the gas exchange process in the
lungs and body. Blood flow is indicated with black arrows and partial pressure
of oxygen and carbon dioxide are indicated in important location throughout
the loop. Interactions between molecules are indicated by arrows.
blood more basic) making hemoglobin’s affinity for oxygen decrease.
We aim to create a mathematical model that focuses on the diffusion of oxygen
and carbon dioxide dynamics over space of a blood capillary in the lungs and body.
Then we will create a loop that accounts for blood exiting the lung to circulate the
body and return to the lung, shown in Figure 17. We modify hemoglobin dynamics
to account for more binding states than the previous model, and discuss a method for
determining pH from carbon dioxide levels and how this is useful for our model. Further details will be discussed, in addition to an explanation of existing mathematical
models, including the model on which our new model is based.
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4.1.2

Mathematical background

Many mathematical models of gas exchange have been studied in the past, however, none of them consider the effects of ventilation associated lung damage with the
inclusion of a model of gas exchange in the body to close the breathing loop [111,
112, 113, 114, 115, 116]. Ben-Tal, 2006 presents the development of a multi-scale
model of gas exchange in the human lung [116]. The author initially models the lung
as a single inflexible compartment, accounting for total pressure averaged over each
alveolus, which accounts only for the fact that the lung can hold air. This simplified
model is then modified to account for the flexibility of the lung by accounting for
the lung as a “container” with a moving plate attached to a spring that causes air to
move in and out. The author introduces variables for the mass, friction, and area of a
plate, along with a spring constant on the spring that moves the plate. The resulting
movement of the plate represents expansion and compression of the lung.
In addition to a model that accounts for basic lung physiology, gas exchange is
introduced into the system. Pulmonary capillaries are accounted for in the model
and blood partial pressures of oxygen and carbon dioxide are also introduced as
parameters. Finally, gas transport is accounted for by allowing for the change in
blood partial pressures of carbon dioxide and oxygen. Blood flow is modeled by
using different containers to account for heartbeat. A large container represents the
input of dissolved gas into the capillary, where it is transported. The main drivers of
transportation of carbon dioxide and oxygen modeled is bicarbonate and hemoglobin,
respectively [116].
Several models exist that explore the pathiophysiology mechanics of certain diseases on lung functionality [117, 118]. Chakraborty et al. (2007) explores hypoxemia
in hepatopulmonary syndrome by creating a multi-scale model of the gas exchange

68

process. The model accounts for shunting of the alveolus in a heightened disease state.
Cox et al. (2009) explores lung dynamics in chronic obstructive pulmonary disorder
(COPD). This model explores how airway inflammation caused by the disease effects
a patients lungs and the lungs ability to adequately oxygenate blood.
Computational fluid dynamics can also be useful in lung modeling efforts, where
air is treated as a fluid flowing into the lung. Fluid dynamics can be useful in exploring
the airway remodeling process and inhalation toxicology [119, 120, 121, 122, 123].
These models analyze shear stress/strain of the trachea and alveolus that results
from mechanical ventilation. Pidaparti et al., 2013 explores stress on the alveolar sac
based on airflow and the geometry of the air sac. Two models are considered with
the geometry of the alveolar sac. One model uses data obtained from a scanning
electron microscope, and the second, an idealized version of the alveolus as a sphere.
The model contains fluid and solid dynamics to account for the air in the alveolus
in addition to the tissue that makes up the outer walls. Traditional Navier-Stokes
equations are used to model air flow and equations of motion for sac wall equations.
The simulations of these models are computationally expensive but the results are
physiologically relevant independent of the alveolus shape used in the model.
The model discussed in this chapter, an extension of Reynolds et al., 2010 [13],
relies on PDEs and accounts for spacial and temporal dynamics of gas exchange in
the capillaries. We aim to create a model of these dynamics that can later be used to
account for inflammation in the lung during different disease states and after periods
of mechanical ventilation. In the next section, we present a detailed discussion of
Reynolds et al., 2010 in order to facilitate a discussion of the new mathematical
model.
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4.2

Previous Mathematical Model
The model presented in Reynolds et al. (2010) focuses on modeling gas ex-

change dynamics in the lung across the capillaries that line the alveolus and the
effect of inflammatory stress on these dynamics. The local dynamics of gas exchange
are explored by modeling a respiratory unit (RU) that consists of approximately 25
alveoli and their surrounding capillaries. The compartments modeled include the
alveolar airspace, tissue lining the alveolar airspace, and the capillary. Partial pressures of oxygen (P O2 ) and carbon dioxide (P CO2 ) are accounted for, in addition
to hemoglobin dynamics and the bicarbonate buffer system dynamics. Diffusion is
assumed to occur from the airspace to the tissue and from the tissue to the blood, as
well as in the other direction. The tissue and capillary that line an RU are modeled
using a uniform grid, broken down into 20 equally spaced units.
Figure 18 shows a schematic of the variables modeled. The interactions between these variables along with inflammation involvement included in the system is
depicted. Inflammatory pathways and inflammatory cell populations will not be explicitly accounted for in our model. It is our intention to create a model that sets the
framework for breathing using a closed loop, such that the values of the blood variables exiting the lung are linked to their levels as they enter the lungs. In Figure 18,
the white/green arrows represent the binding and unbinding of oxygen to hemoglobin
and blue/white arrows represent the dissociation of carbon dioxide into bicarbonate.
These processes are the main drivers of gas exchange in the body and typically occur
in one direction in the lung, where oxygen is moving in from the airspace and carbon
dioxide is moving out into the airspace [13]. A more detailed explanation of the variables and their dynamics are discussed in the next section, where we introduce the
partial differential equations model of the gas exchange in the lung.
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Fig. 17. The model schematic for a single RU is shown. Inflammation is indicated
in this schematic as N0 , N A, N AB , and T N F . Further discussion of these
dynamics, which are omitted for our purposes, can be seen in [13]. Figure 1
from [13] reprinted with permission.
4.2.1

Oxygen Dynamics in the Lung

Reynolds et al. (2010) begins by modeling partial pressure of oxygen in the
alveolus (P O2A ), blood (P O2Bi ), and tissue (P O2T i ) for each spacial unit i. The
equations include diffusion-type terms to account for movement between the alveolar,
blood, and tissue compartments of oxygen and carbon dioxide. Diffusion is modeled in
the traditional sense but with the diffusion from the tissue into the airspace depending
on the sum of the partial pressure over all spacial units in the tissue. This accounts
for the well mixing of the air in the alveolus. Equations (4.1)-(4.3) model diffusion
between compartments where DTOB2 and DTOA2 represent the rate of diffusion of oxygen
between tissue/blood and tissue/alveolus, respectively. The parameters VB0 , VT 0 , and
VA0 represent the volume of blood, tissue, and alveolus, respectively. The constants
σBO2 , σTO2 , σAO2 scale the molar concentration to partial pressuresof oxygen in the blood,
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tissue, and alveolus, respectively.
dP O2Bi
DTOB2 (P O2T i − P O2Bi )
=
dt
σBO2 VB0
P O2T i
DO2 (P O2Bi − P O2T i ) DTOA2 (P O2A − P O2T i )
= TB
+
dt
σTO2 VT 0
σTO2 VT 0
N
dP O2A
DTOA2 X
= O2
(P O2T i − P O2A )
dt
σA VA0 N i=1

(4.1)
(4.2)
(4.3)

Hemoglobin and oxygen dynamics are modeled in the blood by Equations (4.4)(4.6). In this model, hemoglobin dynamics are simplified so that there exists two
states: partially saturated hemoglobin with m = 0.4 oxygen bound, and fully saturated hemoglobin with m = 4 oxygen bound. Partially saturated hemoglobin. Hbm
requires 4 − 3.6 oxygen molecules bind to form HB4 at a rate of k + and detaches
from HB4 to form HBm at a rate of k − . The number of oxygen units needed to go
between these two states was determined so that the overall hemoglobin saturation
is appropriate at moderate and high P O2 levels.

dHBm
m
= k − HB4 − k + HBm P O2B
dt
dHB4
m
= k + HBm P O2B
− k − HB4
dt
m
dP O2B
−k − HB4 − k + HBm P O2B
=m
dt
σBO2

(4.4)
(4.5)
(4.6)

The constant THB indicates the total amount of hemoglobin in the system. Here,
HBm = THB −HB4 since total hemoglobin in the body is conserved. Equations (4.7)(4.8) give the final form of the oxygen dynamics in the blood where the final terms
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account for the blood traversing the capillary at velocity v with a discritized advection
term.

m
dP O2Bi
DTOB2 (P O2T i − P O2Bi )
−k − HB4 − k + (THB − HB4 )P O2B
=
+m
dt
σBO2 VB0
σBO2

(4.7)

− v∇i P O2Bi
dHB4
m
= k + (THB − HB4 )P O2B
− k − HB4 − v∇i HB4i
dt

(4.8)

In order to model the spatial dynamics of oxygen in the tissue component of
the model, we must account for diffusion between the units in this compartment in
addition to the diffusion dynamics into and out of the tissue compartment already
discussed. To do so, we use the second order centered discretization approximation
∇2i for the second derivative, where dynamics in unit i depends on dynamics in units
i − 1 and i + 1. Equation (4.9) gives the final form of tissue oxygen dynamics.

dP O2T i
DTOB2 (P O2Bi − P O2T i ) DTOA2 (P O2A − P O2T i )
=
+
+ DCT ∇2i P CO2T i (4.9)
O2
O2
dt
σT VT 0
σT VT 0

Aside from the oxygen dynamics in the blood and tissue, we must also modify
alveolar oxygen dynamics, Equation (4.3) in order to account for the breath cycle. We
use the smooth Heaviside function, described in Chapter 2.2.2 and given in Equation
(4.10). We also use an inhalation:exhalation ratio of 1:3 with the parameters VC0
representing alveolar ventilation, the air volume taken in during one breath cycle,
and the parameter VAmin0 representing residual volume, the volume left in the lung

73

after exhalation, on an RU. We first derive equations for the change in alveolar volume
on an RU, Equations (4.11)-(4.12) with parameters τ1 and τ2 set so that in tin = 1s
the function y reaches VC0 and decays to zero in tout = 3s. Therefore, the sum of
residual volume VAmin0 and the function y yields the alveolar volume VA0 .

1

sh(t) =

1 + e−20(tin −mod(t,tin +tout )
VC0 sh (t)
y
y0 =
−
τ1
τ2
VA0 (y) = VAmin0 + y

(4.10)
(4.11)
(4.12)

These volumes are used to account for changes in alveolar partial pressure of
oxygen (P O2A ) during a breath cycle. Similar to diffusion, we must convert the
number of oxygen molecules to partial pressure of oxygen. The term VA0 [O2 ] calculates
the number of oxygen molecules and therefore Equation (4.13) models the change in
molecules do to inhaltion rather than diffusion. Equation (4.14) is derived by using
the product rule and assuming that the air oxygen concentration is constant. Dividing
this equation through by σA yields the equation for P O2A , given in Equation (4.16).
The last equation represents change in P O2A only during inhalation and thus, the
overall equation for the partial pressure of oxygen in the air is given in Equation
(4.17)
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d
d
(VA0 (y)[O2 ]) = (VA0 (y)[O2 ]air (t))
dt
dt
d
[O2 ] = ([O2 ]air (t) − [O2 ])R
dt
d
V (y)
dt A0
with R =
VA0 (y)
d
P O2A = R(PO2air − P O2A )
dt

(4.13)
(4.14)
(4.15)
(4.16)

The final equations to account for oxygen dynamics in the lung are given in
Equations (4.17)-(4.20). For further explanation and discussion of the derivation of
these equations, see [13].

N
dP O2A
DTOA2 X
= O2
(P O2T i − P O2A )
dt
σA VA0 N i=1



Inspiration R(PO2air − P O2A )
+


Expiration 0
m
DO2 (P O2T i − P O2Bi )
dP O2Bi
−k − HB4 − k + (THB − HB4 )P O2B
= TB
+
m
dt
σBO2 VB0
σBO2

(4.17)

(4.18)

− v∇i P O2Bi
dHB4
m
= k + (THB − HB4 )P O2B
− k − HB4 − v∇i HB4i
(4.19)
dt
dP O2T i
DO2 (P O2Bi − P O2T i ) DTOA2 (P O2A − P O2T i )
= TB
+
+ DCT ∇2i P CO2T i (4.20)
O2
O2
dt
σT VT 0
σT VT 0
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4.2.2

Carbon Dioxide Dynamics in the Lung

Carbon dioxide dynamics are modeled similarly to oxygen dynamics but accounting for the use of the bicarbonate buffer system. Transport of carbon dioxide in
the body relies in the presence of water molecules in order to dissociate the carbon
dioxide as bicarbonate. These dynamics are modeled using Michaelis-Menten type
terms representing the catalytic reactions between the carbonic acid and bicarbonate
substrates. The parameters kcatCB and kcatHC represent the maximum rate of the
catalytic reactions with CO2 and HCO3− as the substrate, respectively, and the parameters kmCB and kmHC are the Michaelis-Menten constants for the reactions. The
parameters σBC and σTC scale the concentration of carbon dioxide in the blood and
tissue, similar to the σBO2 and σTO2 constants for oxygen. The discretized equations for
carbon dioxide in the blood are given in Equations (4.21)-(4.22)

DC (P CO2T i − P CO2Bi )
dP CO2Bi
= TB
(4.21)
dt
σBC VB


−
1
σBC P CO2Bi
HCO3i
+ C kcatHC
− v∇i P CO2Bi
− − kcatCB
σB
kmCB + σBC P CO2Bi
kmHC + HCO3i
HCO3−
σBC P CO2Bi
dHCO3−
− kcatHC
= kcatCB
(4.22)
dt
kmCB + σBC P CO2Bi
kmHC + HCO3−
− v∇i HCO3−

To finalize the carbon dioxide subsystem, we mimic the derivation of P O2T and
P O2A to create Equations (4.23)-(4.24). The parameter DTCA is the diffusion rate
from tissue to air of carbon dioxide and the constant σAC scales concentration to
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partial pressure of alveolar carbon dioxide.
dP CO2T i
DTCB (P CO2Bi − P CO2T i ) DTCA (P CO2A − P CO2T i )
=
+
dt
σTC VT
σTC VT

(4.23)

+ DCT ∇2i P CO2T i
N
X
dP CO2A
DTCA
= C
(P CO2T i − P CO2A )
dt
σA VA (y)N i=1



Inspiration R(P CO2air − P CO2A )
+


Expiration 0

(4.24)

Collectively, Equations (4.21)-(4.24) model dynamics of carbon dioxide in the
lung. These equations model the dynamics on each RU of the lung, however variability
of blood and tidal volume exists throughout the lung, which will be discussed in the
next section. Further discussion of the derivation of these terms can be found in [13].
4.3

New Model Development
We begin our modeling efforts with the equations described in the previous sec-

tion. To start, we modify the model to include two new waveforms for normal and
mechanical ventilation. The normal ventilation waveform will allow for the uptake of
700mL of air into the alveolar space with inhalation and exhalation times of 1.33 seconds and 2.67 seconds, respectively. The mechanical ventilation waveform will allow
for the uptake of 450mL if air with inhalation and exhalation times of 0.66 seconds
and 1.33 seconds, respectively. These new waveforms are essential parts for the model
in order to later account for the inclusion of lung inflammation when a ventilator is
used. The normal breathing waveform will serve as a baseline on which to analyze
the results of the mechanical ventilation model.
The next adaptation of the existing model is to include three hemoglobin bind-
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ing states. Non-saturated, partially saturated, and fully saturated states will be
accounted for, as opposed to only two in the previous model, which did not explicitly include a zero saturated hemoglobin state. This modification will ensure that
we have a more accurate model of oxygen in the body during several disease and a
more biologically relevant model of ventilation that could be created by extending
this model to include the binding of carbon dioxide to heme groups in later modeling
efforts. In addition, we close the breathing loop of the model to allow for the input
of the lung model to be the output of the body model. To do so, we create a small
length of capillary where blood leaving individual RUs of the lung can mix together.
This creates a way to account for different amounts of blood and oxygen in individual
RUs, depending upon the location of the RU in the lung, allowing for the variability
in oxygen concentration leaving the lung. After the blood mixes, it enters the body
where the gas exchange process continues. Oxygen molecules in the blood will detatch from the hemoglobin and diffuse from the blood into the tissue. On the other
hand, carbon dioxide will move into the blood from the surrounding tissue, where it
will be returned to the lung.
Since there is no additional compartment involved in the gas exchange process in
the body, we account only for dynamics of blood movement through the capillary and
the diffusion of gasses into and out of the tissues in close proximity to the capillary.
Figure 19 illustrates the dynamics of blood moving through a body capillary, into
and out of the tissue located close to the capillary, and then into and out of the tissue
that is some distance away from the surrounding tissue.
4.3.1

Breathing and Mechanical Ventilation Waveforms

The new waveform for normal breathing has the inhalation of 700 mL of air
over one breath cycle (four seconds) is modeled by a sinusoidal equation. Sm is
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Fig. 18. Model schematic for gas exchange in the body. Interaction of Oxygen with
Hemoglobin and Carbon Dioxide with Bicarbonate are shown. In addition,
the diffusion of the gases from the blood to the tissue is indicated by arrows
in the direction they diffusion is expected to occur.
a smooth approximation to the Heaviside function, similar to the one used in the
previous section. In this case tin = 1.33 (inhalation time), tout = 2.67 (exhalation
time) seconds, with ttot = tin + tout , and the Heaviside function causes there to be two
different function definitions for inhalation and exhalation. Specifically, Equations
(4.25) and (4.26) show the functions for inhalation and exhalation, respectively, and
Figure 20 (top) shows the graph of the entire waveform over two breath cycles.



2π
700π
sin
mod (t, ttot ) Sm (tin − mod (t, tin + tout ))
(4.25)
Ain =
2.66
2.66


700π
2π
Aout =
sin
( mod (t, ttot ) + 1.34) (1 − Sm (tin − mod (t, tin + tout ))
5.34
5.34
(4.26)
The new waveform for ventilation with inhalation of 450mL of air over one breath
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cycle (two seconds) is modeled by a constant function for inhalation and an exponential function for exhalation. In this case, inhalation and exhalation occur for
tin = 0.4 and tout = 1.6 seconds. More specifically, Equations (4.26) and (4.27) show
the function for inhalation and exhalation, respectively (bottom of Figure 20).
Kin = 1050Sm mod(t, ttot )
Kout = 428.49e(−2.45 mod(t,ttot )+0.98) (1 − Sm )

4.3.2

(4.27)
(4.28)

Modeling Hemoglobin and Oxygen in the Lung

As described before, oxygen reacts with hemoglobin in the blood of the lung
compartment and attaches to heme groups in order to be carried out of the lung
and into the capillaries of the body where it detaches in order to diffuse out and
oxygenate the tissues of the body. Hemoglobin with no binding sites filled (Hb0 ),
partially saturated (Hbm ), and saturated hemoglobin (Hb4 ) are modeled. We refer
to Hb0 and zero-saturated hemoglobin, Hbm as unsaturated hemoglobin, and Hb4
as saturated hemoglobin. Oxygen binds to Hb0 to form Hbm at the rate k0+ and it
detaches at the rate k0− . Similarly, oxygen binds to Hbm to form Hb4 at the rate
+
+
km
and it detaches at the rate km
. The reaction dynamics are outlined in Equations

(4.29) and (4.30). In the blood, the parameters are related to each other such that
+
k0+ < km
to account for the previously discussed dynamics of hemoglobin’s affinity

for oxygen.
Hb0 + mO2 *
) Hbm

(4.29)

Hbm + (4 − m)O2 *
) Hb4

(4.30)

The equations governing these dynamics, created based on tradition reaction
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Waveforms for Normal Breathing and Mechanical Ventilation
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Fig. 19. The waveforms for normal breathing (top) and ventilation breathing (bottom)
are shown. The normal ventilation waveform has 1.33 second of inhalation and
2.67 seconds of exhalation while the ventilation waveform has 0.67 seconds of
inhalation and 1.33 seconds of exhalation.
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kinetics, are given in Equations (4.31)-(4.34).
d
Hb0 = k0− Hbm − k0+ Hb0 P O2m
dt
d
(4−m)
−
+
Hbm = −k0− Hbm + k0+ Hb0 P O2m + km
Hb4 − km
Hbm P O2
dt
d
(4−m)
−
+
Hb4 = −km
Hb4 + km
Hbm P O2
dt
d
m
4−m −
(4−m)
+
P O2B = (k0− Hbm − k0+ Hb0 P O2m ) +
(km Hb4 − km
Hbm P O2
)
dt
σ
σ

(4.31)
(4.32)
(4.33)
(4.34)

Total concentration of hemoglobin, THB is conserved, so THB = Hb0 +Hbm +Hb4
and Hb0 can be replaced by THB − Hbm − Hb4 . The previous equations reduce to
Equations (4.11)-(4.13).
d
−
Hbm = −k0− Hbm + k0+ (THB − Hbm − Hb4 )P O2m + km
Hb4
dt

(4.35)

(4−m)

+
− km
Hbm P O2

d
(4−m)
−
+
Hb4 = −km
Hb4 + km
Hbm P O2
dt
m
d
P O2B = (k0− Hbm − k0+ (THB − Hbm − Hb4 )P O2m )
dt
σ
4−m −
(4−m)
+
(km Hb4 − km
Hbm P O2
)
+
σ

(4.36)
(4.37)

In this model, the value of the parameter m determines how many oxygen
molecules must be bound to zero-saturated hemoglobin in order for it to be partially
saturated, and subsequently, 4− m oxygen molecules must bind to partially saturated
hemoglobin in order for it to be fully saturated. We assume Quasi-steady state for
partially saturated and saturated hemoglobin and keep the ratios RH0 = k0− /k0+ and
−
+
RHm = km
/km
constant for the chosen values of m. We use hemoglobin saturation

data to fit m, RH0 and RHm with the P O2 saturation curve calculated for this system, Sh =

4P O24 −KHm P O2m (m−4)
.
4(P O24 +P O2m RHm +RH0 RHm )

Any value of the parameter between m = 1.7

and m = 3.6 lead to physiologically relevant oxygen exchange dynamics, so we chose
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the value m = 2.1.
−
+
The values of the ratios of RH0 = k0− /k0+ and RHm = km
/km
are determined using

the desired m-value. The optimal values for these ratios is determined by Equations
(4.38) and (4.39). Hemoglobin saturation percents (Sh ) for partial pressure of oxygen
(P O2 ) levels is known. Thus, we use the points (P O2 , Sh ) on the hemoglobin saturation curve, (0, 0), (80, 0.9), and (50, 0.7), to derive these equations. We then simplify
these equations based on the quasi-steady state of saturation of bound hemoglobin.
RH0 = 0.40e4.38m m − 0.90e3.91m m − 0.16e4.38m + 1.04e3.91m

(4.38)

2.36108
35e4.38m m − 45e3.91m m − 14e4.38m + 54e3.91m

(4.39)

RHm =

We then fit the values for the kx+ parameters based on the known relationship
+
k0+ < km
to account for oxygen affinity to hemoglobin based on the number of oxygen

molecules already bound. Once this values is chosen, we include the blood flow as spatial dynamics in the model, as described before and given in Equations (4.40)-(4.42).
We then discretize the spacial dynamics where ∇i is the discrete approximation of
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the first derivative. The discretized form is shown in Equations (4.43)-(4.45).
d
Hbm = −k0− Hbm + k0+ (THB − Hbm − Hb4 )P O2m
dt
∂
(4−m)
−
+
+ km
Hb4 − km
Hbm P O2
− v HBm
∂x
d
∂
(4−m)
−
+
Hb4 = −km
Hb4 + km
Hbm P O2
− v Hb4
dt
∂x
d
m −
P O2B = O2 (k0 Hbm − k0+ (THB − Hbm − Hb4 )P O2m )
dt
σB
∂
4−m −
(4−m)
+
Hb4 − km
Hbm P O2
) − v P O2
+ O2 (km
∂x
σB
d
Hbm = −k0− Hbm + k0+ (THB − Hbm − Hb4 )P O2m
dt
(4−m)

−
+
+ km
Hb4 − km
Hbm P O2

(4.40)

(4.41)
(4.42)

(4.43)

− v∇i Hbm

d
(4−m)
−
+
Hb4 = −km
Hb4 + km
Hbm P O2
− v∇i Hb4
dt
d
m
P O2B = O2 (k0− Hbm − k0+ (THB − Hbm − Hb4 )P O2m )
dt
σB
4−m −
(4−m)
+
+ O2 (km
Hb4 − km
Hbm P O2
) − v∇i P O2
σB

(4.44)
(4.45)

We use these equations to model oxygen and hemoglobin dynamics that account
for the added hemoglobin state. Equations (4.46)-(4.50) show the final form of the
lung model with the new hemoglobin dynamics included.
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d
Hbm = −k0− Hbm + k0+ (THB − Hbm − Hb4 )P O2m
dt
(4−m)

−
+
+ km
Hb4 − km
Hbm P O2

(4.46)

− v∇i Hbm

d
(4−m)
−
+
Hb4 = −km
Hb4 + km
Hbm P O2
− v∇i Hb4
(4.47)
dt
d
DO2 (P O2T i − P O2Bi )
m
P O2B = T B
+ O2 (k0− Hbm − k0+ (THB − Hbm − Hb4 )P O2m )
C
dt
σB VB
σB
(4.48)
4−m −
(4−m)
+
(km Hb4 − km
Hbm P O2
) − v∇i P O2
O2
σB
DTOB2 (P O2Bi − P O2T i ) DTOA2 (P O2A − P O2T i )
=
+
+ DCT ∇2i P CO2T i (4.49)
O2
O2
σT VT 0
σT VT 0
N
D O2 X
(P O2T i − P O2A )
= O2 T A
σA VA0 N i=1



Inspiration R(PO2air − P O2A )
+


Expiration 0
+
P O2T i
dt
dP O2A
dt

(4.50)
4.3.3

Modeling Blood pH and Carbon Dioxide in the Lung

The carbonic acid buffer system in the blood, reactions shown in Equation (4.51),
is the main driver of blood pH, as previously discussed. The value for pH is typically
calculated by taking a negative logarithm of the molar concentration of hydroxide
ions in a liquid. Experimentally, pH in the blood is easy to measure, so we added it
to this model to facilitate parameter fitting once the inflammatory effects are added.

H + + HCO3− *
) H2 CO3 *
) H2 O + CO2

(4.51)

If inflammation is causing pathological blood conditions when blood is in the
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lung, the level of carbon dioxide may be elevated, and accounting for blood pH could
add a additional level of complexity in the system to help with future analysis. We
use existing variables to create a way to explicitly calculate the pH of blood at a
given spatial unit in Equation (4.52). The derivation of this equation can be found in
literature where [HCO3− ] is the concentration of bicarbonate in the blood in mmol/L,
P O2 is the partial pressure of carbon dioxide in the blood (in mmHg), kCO2 is the
solubility of carbon dixoide and pK 0 is the pK of the HCO3− − CO2 system in the
blood. The values of these are given in literature as kCO2 = .03 and pK 0 = 6.1.
0



pH = pK + log

[HCO3− ]
kCO2 P CO2


(4.52)

This equation can be used to calculate pH of the blood in the lung or body, once
the closed loop breathing model is completed. We do not alter the carbon dioxide
dynamics from the previous model, given in Equations (4.21)-(4.24).
4.3.4
4.3.4.1

Closed Loop Breathing
Well Mixing

We require a closed loop breathing model in order to account for the effect of
accumulated inflammation over multiple breath cycles. The use of RUs in the lung
allows for a more accurate representation of differing oxygen levels in different areas
of the lung and in order to properly model the well mixing of this blood as it exits
the lung, we include a well mixing compartment in the model that is ten spacial units
in length. Different alveolar regions of the lung are defined by the amount of tidal
volume of the lung (Vc ), the amount of air in the lung (Vt ) and the amount of blood
in the capillary (Vb ). This is illustrated in Figure 21.
The equations for the well-mixing compartment have the same form as the blood
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equations in the lung with the diffusion terms between tissue and blood omitted. All
other alveolar and tissue compartment dynamics are excluded and only the interactions between HBm , Hb4 , P O2 , HCO3− , and P CO2 are modeled. The equations
governing these dynamics are given in Equations (4.58)-(4.65).

d
Hbm = −k0− Hbm + k0+ (THB − Hbm − Hb4 )P O2m
dt
(4−m)

−
+
+ km
Hb4 − km
Hbm P O2

(4.53)

− v∇i Hbm

d
(4−m)
−
+
Hb4 = −km
Hb4 + km
Hbm P O2
− v∇i Hb4
(4.54)
dt
d
m
4−m −
(4−m)
+
P O2Bi = O2 (k0− Hbm − k0+ (THB − Hbm − Hb4 )P O2m ) + O2 (km
Hb4 − km
Hbm P O2
)
dt
σB
σB
(4.55)

dP CO2Bi
dt

− v∇i P O2


−
1
HCO3i
σBC P CO2Bi
= C kcatHC
− v∇i P CO2Bi
− − kcatCB
σB
kmCB + σBC P CO2Bi
kmHC + HCO3i
(4.56)

dHCO3−
σBC P CO2Bi
HCO3−
− kcatHC
= kcatCB
dt
kmCB + σBC P CO2Bi
kmHC + HCO3−

(4.57)

− v∇i HCO3−

4.3.4.2

Gas Exchange in the Body

We model gas exchange in the body similar to gas exchange in the lung with the
exclusion of alveolar oxygen and carbon dioxide. Since there is no alveolar air space,
no waveform, breathing variable, or equation of alveolar oxygen and carbon dioxide
are required. The model accounts only for partial pressures of oxygen and carbon
dioxide in the blood (P O2B /P CO2B ) and the tissue (P O2T /P CO2T ). It also accounts
for the three states of hemoglobin, Hb0 , Hbm , and Hb4 , as described in Chapter 4.3.2.
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Fig. 20. The relative position of the lungs and body, as represented in this model.
Prior to entering the body, well-mixing of variables in this model occur [13].
Modified with permission.
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We use the same value of the parameter m for how many oxygen molecules my bind
to zero-saturate hemoglobin in order for form partially saturated hemoglobin. In
addition, we use the same dynamics for the bicarbonate buffer system and model
carbon dioxide dynamics with bicarbonate the same as before. The equations and
parameters governing gas exchange in the body will be the same as those derived in
the lung model.
The code for the calculation of body blood and tissue volumes is given in Appendix C3.1. We assume that the entire blood volume is 5L and that the blood
volume in the lung is 0.9L. We determine the relative size of the tissue compartment
in the body by assuming that the blood unit has a set radius and that we are only
modeling the body tissue within that radius from the blood. We then include the
terms −µO2T i P O2T i and +µCO2T i P CO2T i in the equations to account for the loss of
oxygen to and uptake of carbon dioxide from the surrounding tissue that is not explicitly accounted for in the model. The form of this term is a simple decay depending
upon the amount of oxygen and carbon dioxide in the tissue. The discretized final
model of body dynamics is given in Equations (4.58)-(4.65). Appendix C3.2 shows
the code for the equations of the closed loop breathing model.
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DO2 (P O2Bi − P O2T i )
dP O2T i
+ DO2 T ∇2i P CO2T i − µO2T i P O2T i
= TB
dt
σ O2 VT

(4.58)

DO2 (P O2T i − P O2Bi )
m
dP O2Bi
+ (k0− Hbm − k0+ (THB − Hbm − Hb4 )P O2m )+
= TB
dt
σ
σ O2 VB 0

(4.59)

T

B

4−m −
(4−m)
+
) − v∇i P O2
(km Hb4 − km
Hbm P O2
σ
dHbmi
(4−m)
+
−
Hbm P O2
− v∇i HBm
Hb4 − km
= −k0− Hbm + k0+ (THB − Hbm − Hb4 )P O2m + km
dt
dHb4i
(4−m)
+
−
− v∇i Hb4
Hbm P O2
Hb4 + km
= −km
dt
DC (PC )2T i − P CO2Bi )
dP CO2Bi
1
= TB
+ C
CV 0
dt
σB
σB
B

kcatHC

−
HCO3i

kmHC +

−
HCO3i

− kcatCB

− v∇i P CO2Bi
dP CO2T i
=
dt
−
dHCO3i
=
dt

4.3.4.3

C P CO
σB
2Bi
C P CO
kmCB + σB
2Bi

(4.60)
(4.61)
!
(4.62)
(4.63)

C (P CO
DT
2Bi − P O2T i )
B
+ DCT ∇2i P CO2T i + µCO2T i P CO2T i
O2
σT
VT
−
C P CO
σB
HCO3i
2Bi
−
kcatCB
− v∇i HCO3i
− kcatHC
−
C P CO
kmCB + σB
kmHC + HCO3i
2Bi

(4.64)

(4.65)

Blood and Tidal Volume Variation

We also desire the ability to run analysis with well mixing over many instances
of Vt /Vb combinations. One useful way to create the alveolar regions is to gather a
distribution and divide individual intervals, Vt ∈ [135, 1050] for example, into smaller
intervals, one of which could be Vt0 = [695, 705]. Any value of the distribution chosen
for the tidal volume that falls within that interval is weighted in the well mixing
compartment as the center of the subinterval, Vt0 = 700 in the previous case. This is
called “binning” the distribution and allows use to reduce the computation time of
the model significantly. The results of the “binned” well mixing is then fed into the
body.
Appendix C3.3 shows the code that can perform this distribution where the user
inputs the desired number of simulations, which will be divided up among the bins of
desired length, and the desired range of the distribution. A weight vector is returned
that the user could then apply to a lung code where the user would be responsible
for ensuring that there are enough spacial units and locations in the body to be
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able to accept the number of bins chosen. The computing power required by this
is substantial, so we encourage future generations to perform these techniques when
computers become even more powerful.
In order to avoid massive computation times, we choose three representative
values of Vt /Vb combinations and simulate breathing in well mixing and use the output
as an input to the model of gas exchange in the body. Specifically, three main tidal
and blood variations were used which represent high and low extremes as well as a
mid-range choice. That is, we use the combinations Vt = 700/Vb = 90 to represent
mid-range blood and tidal volumes, and Vt = 350/Vb = 45 and Vt = 1050/Vb = 135
to represent the extremes.
When fitting the model for oxygen dynamics, we use the mid-range values and
aim to have hemoglobin saturate in the first third of the capillary, and we aim for
the desired P O2 levels leaving and entering the lung. Entering the body (leaving the
lung), we desire a high value for P O2 , oscillating within 100-105mmHG, and leaving
the body (entering the lung), we desire a low value for P O2 , oscillating within 4248mmHG. Afterwards, we simulate the same situation with the ventilation waveform
and expect similar results. When fitting the model for carbon dioxide dynamics, we
aim to mimic those dynamics seen in the previous model, saturation in the first tenth
of the capillary. In the next section, we discuss the results of simulations of the model.
4.4

Results
Closed loop breathing under normal ventilation is shown in Figure 18. Hemoglobin

saturation in the case of Vt = 700 and Vb = 90 is shown (top) with the well mixing
and body dynamics (middle and bottom, respectively) are given. Blood oxygen levels
in the lung are similar for each of the cases, where Vt = 350/Vb = 45 lead to a higher
partial pressure and Vt = 1050/Vb = 135 led to a lower partial pressure of oxygen.
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This is intuitive because a larger amount of blood to oxygenate will take a longer time
to oxygenate regardless of the tidal volume because the same amount of air is touching and diffusing through the tissue. On the other hand, when lung tidal volume and
lung blood volume are decreased Vt = 250 and Vb = 45, hemoglobin saturation occurs
much more quickly and blood levels in the lung are increased. When these dynamics
are mixed with the elevated volumes and implemented into the model in the presence
of inflammation, we expect to see reduced tidal and blood volumes due to swelling in
the tissue. At first, this will cause oxygenation of the blood to occur more quickly,
but the lack of blood being oxygenated at any given time will eventually lead to less
oxygenation of tissue in the body and subsequent low oxygen levels entering back into
the lung. Carbon dioxide dynamics are fit in a similar way where the output of the
lung feeds into a well mixing compartment where carbon dioxide and bicarbonate in
the blood combines from different parts in the lung, and the elevated carbon dioxide
output of the body feeds into the lung on the next breath cycle.
Carbon dioxide has similar saturation dynamics as the previous model with closed
loop breathing cause the carbon dioxide levels to enter slightly higher than they did
before. Figure 22 shows carbon dioxide dynamics in the lung in the case of Vt = 700
and Vb = 90 (top) corresponding to body dynamics in which levels increase as carbon
dioxide is picked up through the body capillary (not shown). There is not much
variation in the value of carbon dioxide in the lung, thus the tenth unit of well
mixing ends up being a constant. It is theorized that, because only two varibles are
interacting in the blood of the well mixing compartment, they dynamics are more
simplified than those seen with oxygen. For the normal breathing waveform, the
constant value obtained in the well-mixing compartment was P CO2b = 43.3mmHg,
as seen as the input of the body model, and the out put of the body model was
P CO2B = 44.65mmHg. Uptake of carbon dioxide in the body is relatively steady, as
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seen in the third panel of Figure 22.
When the parameters chosen for normal breathing are implemented using the
waveform for ventilation, we see similar dynamics in oxygenation of the blood of
the lungs and body, however, the hemoglobin saturation in the lung is occurring at
a slightly reduced rate, within the first fifth of the capillary, shown in Figure 23.
Ventilator breathing caused slightly more effective reduction in carbon dioxide levels
in the lung before entering into the body, shown in Figure 24. The tenth unit of the
well-mixing compartment yeilds the value P CO2B = 43.3, which is input into the
body model and the output of the body model is P CO2B = 43.6, which is input into
the lung model.
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Fig. 21. Gas exchange dynamics in the lungs and body are shown under normal breathing. The top panel shows hemoglobin saturation in the lung with Vt = 70, and
Vb = 90, the middle panel shows well mixing of blood leaving the lung, and
the bottom panel show oxygen levels in the body over time. The hemoglobin
saturations and lung oxygen levels are similar for each combination of blood
and tidal volume.
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Fig. 22. Gas exchange dynamics in the lungs and body are shown under normal breathing. In the lung, carbon dioxide is oscillating around 43.5mmHg. Carbon
dioxide is expelled from the lung within the first unit of space (second panel),
and the body removes carbon dioxide from the surrounding tissue at a relatively constant rate.
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Fig. 23. Gas exchange dynamics in the lungs and body are shown under ventilator
breathing. The top panel shows hemoglobin saturation in the lung with
Vt = 70, and Vb = 90, the middle panel shows well mixing of blood leaving the lung, and the bottom panel show oxygen levels in the body over time.
The hemoglobin saturations and lung oxygen levels are similar for each combination of blood and tidal volume.
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Fig. 24. Gas exchange dynamics in the lungs and body are shown under ventilator
breathing. The results of this simulation are similar, but slightly reduced, to
the results of carbon dioxide in normal breathing.
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4.5

Discussion
We created a mathematical model of gas exchange in the lungs and body that

accounts for multiple binding states of hemoglobin and several different instances
of tidal and blood volume in the lung. In order to improve upon past modeling
efforts, we created two breathing waveforms that account for normal breathing and
ventilation breathing, which allowed for the inhaltion of 750mL and 500mL of air,
respectively. The new waveforms cause smaller variation in the gas dynamics in the
model, and therefore change the overall dynamics slightly. In the lung, for oxygen
and carbon dioxide, we see stabilatization of dynamics at an earlier time point in the
new model than we saw in the previous model. If the mesh of the spatial variable
was further refiend, analysis of these results could be performed and this could lend
to futher understanding of how the dyanamics are changing closer to the beginning
of the lung.
The model in its current state sets the stage for future modeling efforts. To
start, future modeling could include a more in-depth analysis of the effect of blood
pH on the system in the presence of increased inflammation in the lung. In so doing,
the inflammatory response can be accounted for under variations of tidal and blood
volume. We expect an increase in inflammation to initially decrease the blood supply
in the capillary, which at first would cause oxygen saturation to occur more quickly
since less blood, means less oxygenation required to fully saturate. However, in
time, this decrease in blood volume and compromised diffusion is expected to become
detrimental.
Also, once computing powers increase, the distribution of tidal and blood volumes
can be expanded to create a well-mixing of blood that more accurately models a
healthy lung. The effect of mechanical ventilation under different waveforms can
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be explored further, as well, in order to determine what inhalation and exhalation
volumes are most efficient without causing damage that cannot be recovered from.
We created a closed loop allows for three different alveolar tidal volume and
blood volume in the lung to mix before entering the body where peripheral tissue
oxygen levels are maintained and carbon dioxide is removed in healthy patients with
both the ventilator and normal breathing waveforms. In the lung, oxygen dynamics
match that of previous models, where hemoglobin saturation occurs within the first
third of the capillary. In it’s current state, the model sets the baseline dynamics for
including inflammation in the lung and analyzing the effect of tissue swelling after
multiple breathe cycles. While inflammation is not explicitly modeled, including it is
possible.
Along with the ability to relate the partial pressure of oxygen to hemoglobin
dynamics in the body, another clinical application of the model is pH. The measuring of pH of blood is a non-invasive test that can easily be performed, and using
the functionality of this model, we can make predictions about future gas exchange
dynamics in mechanical ventilation. In addition to the ability to make predictions
based on lung dynamics, the inclusion of a body part of this model to close the loop
of breathing allows for the analysis of the effects of inflammation over multiple breath
cycles. Therefore, we conclude that this model is a good first step in the efforts of
modeling closed loop breathing in order to later account for gas exchange in clinical
applications.
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CHAPTER 5

CONCLUSION

We developed several mathematical models to describe various processes in the human
body related to inflammation and wound healing. First, we modeled the process of
hematopoiesis in non-diseased and diseased donors undergoing Filgrstim and Plerixafor treatments. We statistically sampled parameters in order to obtain a population
of diseased patients and to explore the effect of Filgrastim and Plerixafor on these patients. This model can be used further to explore timing of Filgrastim administration
and to identify patients that would benefit from early intervention with Plerixafor
rather than have to restart stem cell collection in the rescue situation. This model
can also be extended to account for a specific chemotherapy and radiation treatment.
In addition, the transplantation phase can be modeled in which the initial condition of
the model are set to biological levels representing a patient after stem cells have been
removed and chemotherapy has been performed. The underlying dynamics may need
altering to account for the repopulation of peripheral stem cells pool in the spleen
and lymph nodes. Comparisons can be done based on differing biological dynamics
and drug effectiveness in the process to model other disease states.
Next, we modeled the inclusion of two immune cell populations in the wound
healing response in addition to the effect of the systemic mediator estrogen on this
process. The model can be extended to account for the remainder of the wound
healing process, the accumulation of collagen in the presence of fibroblasts and how
the presence of systemic mediators effect this process. Wound healing models that
account for the difference in gender could later be used to look at diabetic ulcers and
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wound healing post trauma.
Last, we modeled gas exchange in a closed loop by accounting for well mixing of
the blood leaving different parts of the lung, and gas exchange dynamics in the body.
Two waveforms were implemented in three different tidal volume circumstances. The
inflammatory response can be included in this model of closed loop breathing so the
effect of its presence in the lung can be studied over time. In addition, the well
mixing compartment of the lung can be altered so that a distribution of lung and
blood volumes can feed into this compartment in order to model a more biologically
accurate lung.
Mathematical modeling of physiological processes is useful in the medical fields
as it can help doctors and professionals gain insight into the underlying dynamics of
a disease. Expansion and further development of the models presented here could
lead to models that cal help physicians chose an optimal treatment.
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Appendix A

PATIENT DATA USED TO FIT THE MATHEMATICAL MODEL
HEMATOPOIETIC BONE MARROW STEM CELLS

This Appendix shows patient data used in parameter fitting for the mathematical
model of hematopoietic bone marrow stem cells. Data was collected at the Virginia
Commonwealth University Medical College of Virginia in patients undergoing stem
cell collection and/or treatment at the Massey Cancer Center.
A.1

Blood cell count data for donor patients treated with Filgrastim
Patient
Number

Day 1
Collection

Day 2
Collection

4316763
4370359
4392643
4310102
4323631
4324684
4324799
4331005
4333239
4338440
4358957
4359957
4380355
5381996
6076532
4346288
4353937
4393216
4341190
4378512

614.3181818
1369.581818
761.9090909
73.24090909
302.4454545
130.4545455
114.0363636
161.1
523.8863636
401.8636364
549.4
214.6909091
695.7954545
148.2545455
583.6363636
77.07272727
80.32727273
270
106.91
131.56

216.15
384.8454545
384.3636364
462.5454545
379.8
334.6818182
703.5
88.70909091
133.2363636
541.5681818
581.2363636
650.7545455
131.3090909
264.0545455
285
159.27
154.15

Average
St. Deviation

365.5243182
329.190129

344.4219251
191.7987087

Day 3
Collection

Day 4
Collection

Total cells collected
(×106 )

124.8863636
387.1090909
145
171.64
125.67

86.55
84.44

614.3181818
1369.581818
761.9090909
289.3909091
687.2909091
514.8181818
576.5818182
540.9
858.5681818
1105.363636
638.1090909
347.9272727
1237.363636
729.4909091
1234.390909
333.2681818
731.4909091
700
524.36
495.82

190.8609091
111.3421469

85.49090909
1.491352484

714.5472727
307.7383107
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Appendix B

ABBREVIATIONS AND VARIABLES

VILI
PB
BM
LHS
G-CSF
C
P
P
Lc
Rc
Nc
Lm
Rm
Nm
L
R
N
N
Df
Dp
M
Pt
P O2t
P O2b
P CO2t
P CO2b
Hb0
Hbm
Hb4
HCO3−

Ventilation Induced Lung Injury
Peripheral Blood
Bone Marrow
Latin-Hypercube Sampling
Granulocyte-Colony Stimulating Factor
Hematopoietic Stem Cell Variable
Chapter 2-Peripheral Blood Stem Cell Variable
Chapter 3-Pathogen Variable
Committed Platelet Variable
Committed Red Blood Cell Variable
Committed Immune Cell Variable
Mature Platelet Variable
Mature Red Blood Cell Variable
Mature Immune Cell Variable
Platelet Variable
Red Blood Cell Variable
Chapter 1-Immune Cell Variables
Chapter 2-Neutrophil Variable
Filgrastim Drug Effectiveness Variable
Plerixafor Drug Effectiveness Variable
Macrophage Variable
Platelet Variable
Partial Pressure of Oxygen in the Tissue
Partial Pressure of Oxygen in the Blood
Partial Pressure of Carbon Dioxide in the Tissue
Partial Pressure of Carbon Dioxide in the Blood
Concentration of Zero-Saturated Hemoglobin
Concentration of Partially-Saturated Hemoglobin
Concentration of Fully-Saturated Hemoglobin
Concentration of Bicarbonate in the Blood
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Appendix C

CODE

C.1

Mathematical Model of Hematopoiesis

• Mathematical Model of Steady State of Hematopoiesis
function system=stemcellsystem8_ss(t,x,U,D)
%This function is the steady state function for the Stem Cell system.
%Open the file for variables and parameter names and their index.
%This file should be run from the corresponding run file: run8_ss().
%
%
% tau1=.2;
% tau2=0.025;
%
% ton=3.25;
% toff=24-ton;
system=[((U(1)*x(1))/(1+((x(8)+x(9)+x(10))/U(29))))-...
(U(7)+U(8)+U(9)...+U(16))*x(1)+(U(6)/U(28))*(x(11)-...
x(1));...%x(1)=C
((U(2)*x(2))/(1+(x(8)/U(30))))+U(7)*x(1)-U(10)*x(2)...
-U(18)*x(2);...%x(2)=Rc
((U(3)*x(3))/(1+(x(9)/U(31))))+U(8)*x(1)-U(11)*x(3)...
-U(19)*x(3);...%x(3)=Lc
((U(4)*x(4))/(1+(x(10)/U(32))))+U(9)*x(1)-U(12)*x(4)...
-U(20)*x(4);...%x(4)=Nc
U(10)*x(2)-(U(13)/U(28))*x(5)-U(21)*x(5);...%x(5)=Rm
U(11)*x(3)-(U(14)/U(28))*x(6)-U(22)*x(6);...%x(6)=Lm
U(12)*x(4)-(U(15)/U(28))*x(7)-U(23)*x(7);...%x(7)=Nm
(U(13)/U(27))*x(5)-U(24)*x(8);...%x(8)=R
(U(14)/U(27))*x(6)-U(25)*x(9);...%x(9)=L
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(U(15)/U(27))*x(7)-U(26)*x(10);...%x(10)=N
((U(5)*x(11))/(1+((x(1)+x(11))/U(33))))+(U(6)/U(27))*...
(x(1)-x(11))-...U(17)*x(11);...%x(11)=P
x(12)*(D(7)-x(12))*D(1)*sm(t,D(5),D(6))-D(2)*...
x(12);...%x(12)=Df -- %Filgrastim
x(13)*(D(8)-x(13))*D(3)*sm(t,D(5),D(6))-D(4)...
*x(13);...%x(13)=Dp -- Plerixafor
0*x(10);...%x(14)=N-removal
0*x(9);...%x(15)=L-removal
0*x(11);%x(16)=P-removal
];

%% Parameters and Variables for ALL the models, not just the
% steady state model
%% Equilibrium Parameters
%U(1)=sc
%2=src
%3=slc
%4=snc
%5=sp
%6=kcp

%% Variables

%27vb
%28vm
%29cinf %x(2)=Rc
%30rinf
%31linf
%32ninf
%33pinf

%7=kcrc
%8=kclc
%9=kcnc

%x(1)=C

%x(3)=Lc
%x(4)=Nc
%x(5)=Rm
%x(6)=Lm
%x(7)=Nm
%x(8)=R
%x(9)=L
%x(10)=N

%10=krcm
%11=klcm
%12=kncm
%13=krmr
%%14=klml
%15=knmn

%x(11)=P
%x(12)=Df
%x(13)=Dp
%x(14)=Nremoval
%x(15)=Lremoval
%x(16)=Premoval

%16=muc
%17=mup
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%18=murc
%19=mulc
%20=munc
%21=murm
%22=mulm
%23=munm
%24mur
%25mul
%26mun
%% %Drug Parameters
%D(1)=tau1f
%D(2)=tau2f
%D(3)=tau1p
%D(4)=tau2p
%D(5)=ton
%D(6)=toff
%D(8)=xsp
%D(9)=kscf
%D(10)=ksncf
%D(11)=kcpf
%D(12)=krcpf
%D(13)=klcpf
%D(14)=kncpf
%D(15)=kpcp
%D(16)=mu_r
%D(17)=mu_n
%D(18)=mu_p

• Mathematical Model of Drug Treatment in Hematopoiesis
function system=stemcellsystem8_dt(t,x,U,D)
%This function is the drug treatment (filgrastim and
plerixafor) function
%for the Stem Cell system. Open tte file for variables
and parameter names
%and their index. This file should be run from the
corresponding run file:
% run8_dt().
%Loading a workspace with correct parameter values
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may also be necessary
%
Don=1;
D(3)=0;D(4)=0;D(8)=0;D(15)=0;
%D(3)=0.2;D(4)=0.025;D(8)=1.1;D(15)=1000;
system=[(((U(1)*x(1))*(1+D(9)*x(12)))/(1+((x(8)+x(9)+...
x(10))/U(29))))-(U(7)+U(8)+U(9)+U(16))*x(1)+(U(6)/...
U(28))*(1+D(11)*x(12)+D(15)*x(13))*(x(11)-x(1));...%x(1)=C
((U(2)*x(2))/(1+(x(8)/U(30))))+U(7)*x(1)-U(10)*x(2)-U(18)*...
x(2)-Don*((D(12)*x(12))/(U(28)))*x(2);...%x(2)=Rc
((U(3)*x(3))/(1+(x(9)/U(31))))+U(8)*x(1)-U(11)*x(3)-U(19)*...
x(3)-Don*((D(13)*x(12))/(U(28)))*x(3);...%x(3)=Lc
(((U(4)*x(4))*(1+D(10)*x(12)))/(1+(x(10)/U(32))))+U(9)*...
x(1)-U(12)*x(4)-U(20)*x(4)-Don*((D(14)*x(12))/(U(28)))*x(4);...
%x(4)=Nc
U(10)*x(2)-(U(13)/U(28))*x(5)-U(21)*x(5);...%x(5)=Rm
U(11)*x(3)-(U(14)/U(28))*x(6)-U(22)*x(6);...%x(6)=Lm
U(12)*x(4)-(U(15)/U(28))*x(7)-U(23)*x(7);...%x(7)=Nm
(U(13)/U(27))*x(5)-U(24)*x(8);...%x(8)=R
(U(14)/U(27))*x(6)-U(25)*x(9);...%x(9)=L
(U(15)/U(27))*x(7)-U(26)*x(10);...%x(10)=N
((U(5)*x(11))/(1+((x(1)+x(11))/U(33))))+(U(6)/U(27))*...
(1+D(11)*x(12)+D(15)*x(13))*(x(1)-x(11))-U(17)*x(11)...
+Don*(((D(12)*x(12))/(U(27)))*x(2)+((D(13)*x(12))/...
(U(27)))*x(3)+((D(14)*x(12))/(U(27)))*x(4));...%x(11)=P
x(12)*(D(7)-x(12))*D(1)*sm(t,D(5),D(6))-D(2)*x(12);...
%x(12)=Df -- Filgrastim
x(13)*(D(8)-x(13))*D(3)*sm(t,D(5),D(6))-D(4)*x(13);...
%x(13)=Dp -- Plerixafor
0*x(10);...%x(14)=N-removal
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0*x(9);...%x(15)=L-removal
0*x(11);%x(16)=P-removal
];

• Mathematical Model of Removal in Hematopoiesis
function system=stemcellsystem8_r(t,x,U,D)
%This function is the drug treatment (filgrastim and plerixafor)
%function for the Stem Cell system. Open tte file for variables and
%parameter names and their index. This file should be run from
%the corresponding run file: run8_dt().
%Loading a workspace with correct parameter values
%may also be necessary
%
Don=1;
system=[(((U(1)*x(1))*(1+D(9)*x(12)))/(1+((x(8)+x(9)+x(10))/...
U(29))))-(U(7)+U(8)+U(9)+U(16))*x(1)+(U(6)/... U(28))*(1+D(11)*...
x(12))*(x(11)-x(1));...%x(1)=C
((U(2)*x(2))/(1+(x(8)/U(30))))+U(7)*x(1)-U(10)*x(2)-U(18)*x(2)-Don*...
((D(12)*x(12))/(U(28)))*x(2);...%x(2)=Rc
((U(3)*x(3))/(1+(x(9)/U(31))))+U(8)*x(1)-U(11)*x(3)-U(19)*x(3)-Don*...
((D(13)*x(12))/(U(28)))*x(3);...%x(3)=Lc
(((U(4)*x(4))*(1+D(10)*x(12)))/(1+(x(10)/U(32))))+U(9)*x(1)-U(12)*...
x(4)-U(20)*x(4)-Don*((D(14)*x(12))/(U(28)))*x(4);...%x(4)=Nc
U(10)*x(2)-(U(13)/U(28))*x(5)-U(21)*x(5);...%x(5)=Rm
U(11)*x(3)-(U(14)/U(28))*x(6)-U(22)*x(6);...%x(6)=Lm
U(12)*x(4)-(U(15)/U(28))*x(7)-U(23)*x(7);...%x(7)=Nm
(U(13)/U(27))*x(5)-U(24)*x(8);...%x(8)=R
(U(14)/U(27))*x(6)-U(25)*x(9)-D(17)*x(9);...%x(9)=L
(U(15)/U(27))*x(7)-U(26)*x(10)-D(16)*x(10);...%x(10)=N
((U(5)*x(11))/(1+((x(1)+x(11))/U(33))))+(U(6)/U(27))*(1+D(11)*...
x(12))*(x(1)-x(11))-U(17)*x(11)+Don*(((D(12)*x(12))/(U(27)))*x(2)...
+((D(13)*x(12))/(U(27)))*x(3)+((D(14)*x(12))/(U(27)))*x(4))-D(18)...
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*x(11);...%x(11)=P
x(12)*(D(7)-x(12))*D(1)*sm(t,D(5),D(6))-D(2)*x(12);...
%x(12)=Df -- Filgrastim
x(13)*(D(8)-x(13))*D(3)*sm(t,D(5),D(6))-D(4)*x(13);...
%x(13)=Dp -- Plerixafor
D(16)*x(10);...%x(14)=N-removal
D(17)*x(9);...%x(15)=L-removal
D(18)*x(11);%x(16)=P-removal
];
\end{vertbatim}
\normalsize
\item Mathematical Model of Hematopoiesis Following Removal
\small
\begin{verbatim}
function system=stemcellsystem8_ar(t,x,U,D)
%This function is the drug treatment (filgrastim and plerixafor)
%function for the Stem Cell system. Open the _ss file for variables
%and parameter names and their index. This file should be run
%from the corresponding run file: run8_dt().
%Loading a workspace with correct parameter values is also necessary
Don=1;
system=[(((U(1)*x(1))*(1+D(9)*x(12)))/(1+((x(8)+x(9)+x(10))/...
U(29))))-(U(7)+U(8)+U(9)+U(16))*x(1)+(U(6)/U(28))*(1+D(11)*...
x(12))*(x(11)-x(1));...%x(1)=C-HSCs in the BM
((U(2)*x(2))/(1+(x(8)/U(30))))+U(7)*x(1)-U(10)*x(2)-U(18)*x(2)-...
Don*((D(12)*x(12))/(U(28)))*x(2);...%x(2)=Rc-Committed RBCs
((U(3)*x(3))/(1+(x(9)/U(31))))+U(8)*x(1)-U(11)*x(3)-U(19)*x(3)-...
Don*((D(13)*x(12))/(U(28)))*x(3);...%x(3)=Lc-Committed Plateleta
(((U(4)*x(4))*(1+D(10)*x(12)))/(1+(x(10)/U(32))))+U(9)*x(1)-U(12)...
*x(4)-U(20)*x(4)-Don*((D(14)*x(12))/(U(28)))*x(4);...
%x(4)=Nc-Committed neutrophils
U(10)*x(2)-(U(13)/U(28))*x(5)-U(21)*x(5);...%x(5)=Rm-mature RBCs
U(11)*x(3)-(U(14)/U(28))*x(6)-U(22)*x(6);...%x(6)=Lm-Mature platelets
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U(12)*x(4)-(U(15)/U(28))*x(7)-U(23)*x(7);...%x(7)=Nm-Mature Neutorophils
(U(13)/U(27))*x(5)-U(24)*x(8);...%x(8)=R-RBCs
(U(14)/U(27))*x(6)-U(25)*x(9);...%x(9)=L-Platelets
(U(15)/U(27))*x(7)-U(26)*x(10);...%x(10)=N-Neutrophils
((U(5)*x(11))/(1+((x(1)+x(11))/U(33))))+(U(6)/U(27))*...
(1+D(11)*x(12))*(x(1)-x(11))-U(17)*x(11)+Don*(((D(12)*...
x(12))/(U(27)))*x(2)+((D(13)*x(12))/(U(27)))*x(3)+((D(14)*...
x(12))/(U(27)))*x(4));...%x(11)=P-HSCs in the PB
-D(2)*x(12);...%x(12)=Df -- Filgrastim
-D(4)*x(13);...%x(13)=Dp -- Plerixafor
0*x(10);...%x(14)=N-removal
0*x(9);...%x(15)=L-removal
0*x(11);%x(16)=P-removal
];

C.2

Mathematical Model of the Inflammatory Response

function dydt = RHS_subsystem_27p(t,y,parameters)
%The RHS of the inflammatory response used for parameter sampling

kpg = parameters(1);kptn = parameters(2);kptm = parameters(3);
nai = parameters(4);Ca = parameters(5);Cinf = parameters(6);
mupt = parameters(7);pinf = parameters(8);kpb = parameters(9);
sb = parameters(10);
mub = parameters(11);kbp = parameters(12);kpn = parameters(13);
kpm = parameters(14);snr = parameters(15);knp = parameters(16);
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knpt = parameters(17); munr = parameters(18);mun = parameters(19);
mum = parameters(20);
knm = parameters(21);smr = parameters(22);kmp = parameters(23);
kmm = parameters(24);kmn = parameters(25);kmpt = parameters(26);
mumr = parameters(27);
% EQUATIONS
%Debris Equation
dPt = -kptn*y(3)*y(1)-kptm*y(4)*y(1)*inhib_f(y(3),nai,2)+mun*y(3)-mupt*y(1);
%Pathogen Equation
dP = kpg*y(2)*(1-(y(2)/pinf))-(kpb*sb*y(2)/(mub+kbp*y(2)))-kpn*y(3)*y(2)...
-kpm*y(4)*y(2)*inhib_f(y(3),nai,2);
%Neutrophil Equation
dN = snr*R1(y(2), y(1), knp, knpt, 1, Ca, Cinf,2)/(munr+R1(y(2), y(1), ...
knp, knpt,1, Ca, Cinf,2))-mun*y(3)-knm*y(4)*y(3)*inhib_f(y(3),nai,2);
%Macrophage Equation
dM = smr*R2(y(2), y(4), y(3), y(1), kmp, kmm, kmn, 1, kmpt, Ca, Cinf,2)/...
(mumr+R2(y(2), y(4), y(3), y(1), kmp, kmm, kmn, 1, kmpt, Ca, Cinf,2) )...
+-mum*y(4);
dydt = [dPt; dP; dN; dM];
C.3
C.3.1

Mathematical Model of Closed Loop Breathing
Calculation of Blood and Tissue Volumes in the Body

function [h,vb0_div,vb0_tot,vt0_tot] = calc_vols(n,m,blv,s)
% Choose n = desired number of spatial units of capillary,
% m = desired total length of capillary,
% blv = desired volume of blood in lung, (0.9 in previous model) -- ((may end
% up being a function of time later))
% s = (function) length of tissue between the end of the blood vessel and
%the end of the tissue relative to the radius of the tissue
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%
%
%
%

Output:
h = grid size
r = radius of capillary
vb0, vt0 = volume (size) of blood and tissue, respectively.

h=m/n;
vb0_tot=5-blv;
vb0_div=vb0_tot/n;
r=sqrt((vb0_div/n)/(pi*h));
s_new=r+s(r);
vt0p=(pi*h*(s_new)^2);
vt0_div=vt0p*n-vb0_div;
vt0_tot=vt0_div*n;

C.3.2

Mathematical Model of Closed Loop Breathing

• Hemoglobin Parameters for Oxygen Dynamics
function [ratio0,ratiom]=calculate_ratios(m);
format long
ratio0=.3973467831*exp(4.382026635*m)*m-.8680172925*...
exp(3.912023005*m)*m-.1589387132*exp(4.382026635*m)+...
1.041620751*exp(3.912023005*m);
ratiom=2.35940000*10^8/(35.*exp(4.382026635*m)*m-45...
.*exp(3.912023005*m)*m-14.*exp(4.382026635*m)+54...
.*exp(3.912023005*m));

• Mathematical Model of Closed Loop Breathing
function r = dx_lung_o2(t,X,data1,data2,data3)
r=zeros(81,1);
% Spacial unit size--tissue length is 0.2199cm, so h=.2199/20
h_lung=0.011;
h_wm=0.011;
[h_body,~,vbb,~] = calc_vols(200,4.8,.9,@(x)x);
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% Diffusion parameters
do2_tb=2.9e-11;do2_ta=2.9e-12;
d_gt=3.24e-5;
% Sigmas that scale partial pressures to molar concentration
sigma_o2=1.47e-6;sigma_air=5.2e-5;
% Hemoglobin parameters
m=2.1;kmplus=0.005;k0plus=0.05;
hbtotal=2.24e-3;
[ratio0,ratiom]=calculate_ratios(m);
k0minus=ratio0*k0plus;kmminus=ratiom*kmplus;
% Gas levels in the air that is being inhaled and speed of blood
gair0=104;v0=0.018;v=v0;
% Alveolus count and scaling
auc=0.12e8;auc_L=auc*1000;
% Waveform; integrated equation representation
WF_flag=0;
if WF_flag==0; %normal waveform
tin=1.33;
tout=4-tin;
in=(-350*cos(2.362099739*mod(t,tin+tout))+350)*sm(t,tin,tout);
out=(349.9999999*sin(1.176626462*mod(t,tin+tout)+...
0.005883132285)...
+350)*(1-sm(t,tin,tout));
elseif WF_flag==1; %vent waveform
tin=0.4;
tout=2-tin;
in=1050*mod(t,tin+tout).*sm(t,tin,tout);
out=428.4866433*exp(-2.450484785.*mod(t,tin+tout)+...
.9801939140).*...
(1-sm(t,tin,tout));
end
y=(in+out)/auc_L;
%% Lung Oxygen
% DE for oxygen in the alveolar space
r(1)=do2_ta*(1/20)*(sum(X(2:21),1)-20*X(1))/(sigma_air*...
va(t,data1,y))+max(rv(t,data1,auc,tin,tout,y,WF_flag),0)*...
(gair0-X(1));
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vtt=vtfunc(t,data1);
vbb=vbfunc(t,data1);
% DE for oxygen in the tissue over 20 spacial units (2:21)
r(2)=do2_ta*(X(1)-X(2))/(sigma_o2*vtt)+do2_tb*(X(22)-X(2))/...
(sigma_o2*vbb)+d_gt*(X(3)-2*X(2)+X(2))/h_lung^2;
for i=3:1:20
r(i)=do2_ta*(X(1)-X(i))/(sigma_o2*vtt)+do2_tb*(X(i+20)-...
X(i))/(sigma_o2*vbb)+...
d_gt*(X(i+1)-2*X(i)+X(i-1))/h_lung^2;
end
r(21)=do2_ta*(X(1)-X(21))/(sigma_o2*vtt)+do2_tb*...
(X(41)-X(21))/(sigma_o2*vbb)+d_gt*(X(20)-2*X(21)+X(21))...
/h_lung^2;
% DE for oxygen in the blood over 20 spacial units (22:41)
r(22)=do2_tb*(X(2)-X(22))/(sigma_o2*vbb)+...
(m/sigma_o2)*(k0minus*X(42)-(k0plus*(hbtotal-X(42)-X(62))
*X(22)^m))+((4-m)/sigma_o2)*(kmminus*X(62)-kmplus*...
X(42)*X(22)^(4-m))-v*(X(22)-io2b)/h_lung;
for i=23:1:41
r(i)=do2_tb*(X(i-20)-X(i))/(sigma_o2*vbb)+...
(m/sigma_o2)*(k0minus*X(i+20)-(k0plus*(hbtotal-...
X(i+20)-X(i+40))*X(i)^m))+((4-m)/sigma_o2)*...
(kmminus*X(i+40)-kmplus*X(i+20)*X(i)^(4-m))...
-v*(X(i)-X(i-1))/h_lung;
end
% DE for unsaturated hemoglobin in the blood over 20 spacial units
r(42)=-k0minus*X(42)+k0plus*(hbtotal-X(42)-X(62))*...
X(22)^m+kmminus*X(62)-kmplus*X(42)*X(22)^(4-m)-v*...
(X(42)-ihbm)/h_lung;
for i=43:1:61;
r(i)=-k0minus*X(i)+k0plus*(hbtotal-X(i)-X(i+20))*X(i-20)^m+...
kmminus*X(i+20)-kmplus*X(i)*X(i-20)^(4-m)-v*(X(i)-...
X(i-1))/h_lung;
end
% DE for saturated hemoglobin in the blood over 20 spacial units
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r(62)=-kmminus*X(62)+kmplus*X(42)*X(22)^(4-m)-...
v*(X(62)-ihb4)/h_lung;
for i=63:1:81
r(i)=-kmminus*X(i)+kmplus*X(i-20)*X(i-40)^(4-m)-v*...
(X(i)-X(i-1))/h_lung;
end
%% Lung Carbon Dioxide
% DE for alveolar carbon dioxide
r(82)=dco2_ta*(1/20)*(sum(X(83:102),1)-20*X(82))/...
(sigma_air*va(t,data1,y))+...
max(rv(t,data1,auc,tin,tout,y,WF_flag),0)*(cair0-X(82));
vtt=vtfunc(t,data1);
vbb=vbfunc(t,data1);
% DE for partial pressure of co2 in the tissue over 20 spacial units
r(83)=dco2_ta*(X(82)-X(83))/(sigma_co2*vtt)+dco2_tb*...
(X(103)-X(83))/(sigma_co2*vbb)+d_ct*(X(84)-2*...
X(83)+X(83))/h_lung^2;
for i=84:1:101
r(i)=dco2_ta*(X(82)-X(i))/(sigma_co2*vtt)+dco2_tb*(X(i+20)-...
X(i))/(sigma_co2*vbb)+d_ct*(X(i+1)-2*X(i)+X(i-1))/h_lung^2;
end
r(102)=dco2_ta*(X(82)-X(102))/(sigma_co2*vtt)+dco2_tb*...
(X(122)-X(102))/(sigma_co2*vbb)+d_ct*(X(102)-2*...
X(101)+X(101))/h_lung^2;
% DE for partial pressure of co2 in the blood over 20 spacial units
r(103)=dco2_tb*(X(83)-X(103))/(sigma_co2*vbb)+((1/sigma_co2)...
*(kcat_hco3*(X(123)/(km_hco3+X(123)))-kcat_co2*(sigma_co2...
*X(103)/(km_co2+sigma_co2*X(103)))))+d_ct*(X(103)-ico2b)/...
h_lung^2;
for i=104:1:122
r(i)=dco2_tb*(X(i-20)-X(i))/(sigma_co2*vbb)+((1/sigma_co2)*...
(kcat_hco3*(X(i+20)/(km_hco3+X(i+20)))-kcat_co2*...
(sigma_co2*X(i)/(km_co2+sigma_co2*X(i)))))+...
d_ct*(X(i)-X(i-1))/h_lung^2;
end
% DE for bicarbonate in the blood over 20 spacial units (123:142)
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r(123)=kcat_co2*(sigma_co2*X(103)/(km_co2+sigma_co2*...
X(103)))-kcat_hco3*(X(123)/(km_hco3+X(123)))-v*(X(123)-...
ihco3)/h_lung;
for i=124:1:142
r(i)=kcat_co2*(sigma_co2*X(i-20)/(km_co2+sigma_co2*X(i-20)))-...
kcat_hco3*(X(i)/(km_hco3+X(i)))-v*(X(i)-X(i-1))/h_lung;
end
% DE for oxygen in the wellmixing compartment over 10 spacial units
r(143)=(m/sigma_o2)*(k0minus*X(153)-(k0plus*(hbtotal-X(153)-...
X(163))*X(143)^m))+((4-m)/sigma_o2)*(kmminus*X(163)-...
kmplus*X(153)*X(143)^(4-m))-v*(X(143)-io2b_fromlung)/h_wm;
for i=144:1:152
r(i)=(m/sigma_o2)*(k0minus*X(i+10)-(k0plus*(hbtotal-X(i+10)-...
X(i+20))*X(i)^m))+((4-m)/sigma_o2)*(kmminus*X(i+20)-...
kmplus*X(i+10)*X(i)^(4-m))-v*(X(i)-X(i-1))/h_wm;
end
% DE for unsaturated hemoglobin in the well mixing compartment
% over 10 spacial units
r(153)=-k0minus*X(153)+k0plus*(hbtotal-X(153)-X(163))*...
X(143)^m+kmminus*X(163)-kmplus*X(153)*X(143)^(4-m)-...
v*(X(153)-ihbm_fromlung)/h_wm;
for i=154:162
r(i)=-k0minus*X(i)+k0plus*(hbtotal-X(i)-X(i+10))*X(i-10)^m+...
kmminus*X(i+10)-kmplus*X(i)*X(i-10)^(4-m)-v*(X(i)-X(i-1))/h_wm;
end
% DE for saturated hemoglobin in the well mixing compartment
%over 10 spacial units
r(163)=-kmminus*X(163)+kmplus*X(153)*X(143)^(4-m)-v*(X(163)-...
ihb4_fromlung)/h_wm;
for i=164:172
r(i)=-kmminus*X(i)+kmplus*X(i-10)*X(i-20)^(4-m)-v*(X(i)-X(i-1))/h_wm;
end
% DE for partial pressure of co2 in the blood in the wm comp over 10 spacial units
r(173)=((1/sigma_co2)*(kcat_hco3*(X(183)/(km_hco3+X(183)))...
-kcat_co2*(sigma_co2*X(173)/(km_co2+sigma_co2*X(173)))))+...
d_ct*(X(173)-ico2b_fromlung)/h_wm^2;
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for i=174:1:182
r(i)=((1/sigma_co2)*(kcat_hco3*(X(i+10)/(km_hco3+X(i+10)))...
-kcat_co2*(sigma_co2*X(i)/(km_co2+sigma_co2*X(i)))))+...
d_ct*(X(i)-X(i-1))/h_wm^2;
end
% DE for bicarbonate in the blood of the wm comp over 10 spacial units
r(183)=kcat_co2*(sigma_co2*X(173)/(km_co2+sigma_co2*X(173)))-...
kcat_hco3*(X(183)/(km_hco3+X(183)))-v*(X(183)-ihco3_fromlung)/h_wm;
for i=184:1:192
r(i)=kcat_co2*(sigma_co2*X(i-10)/(km_co2+sigma_co2...
*X(i-10)))-kcat_hco3*(X(i)/(km_hco3+X(i)))-v*...
(X(i)-X(i-1))/h_wm;
end
% DE for oxygen in the tissue over 200 spacial units
r(193)=do2_tb*(X(393)-X(193))/(sigma_o2*vbb)+d_gt*...
(X(194)-2*X(193)+X(193))/h_body^2;
for i=194:391
r(i)=do2_tb*(X(i+200)-X(i))/(sigma_o2*vbb)+d_gt*(X(i+1)-...
2*X(i)+X(i-1))/h_body^2;
end
r(392)=do2_tb*(X(41)-X(392))/(sigma_o2*vbb)+d_gt*(X(391)-...
2*X(392)+X(392))/h_body^2;
% DE for oxygen in the blood over 200 spacial units (22:41)
r(393)=do2_tb*(X(193)-X(393))/(sigma_o2*vbb)+...
(m/sigma_o2)*(k0minus*X(593)-(k0plus*(hbtotal-X(593)-...
X(793))*X(393)^m))+((4-m)/sigma_o2)*(kmminus*...
X(793)-kmplus*X(593)*X(393)^(4-m))-v*(X(393)-io2b_fromwm)...
/h_body;
for i=394:592
r(i)=do2_tb*(X(i-200)-X(i))/(sigma_o2*vbb)+...
(m/sigma_o2)*(k0minus*X(i+200)-(k0plus*(hbtotal-X(i+200)-...
X(i+400))*X(i)^m))+((4-m)/sigma_o2)*(kmminus*X(i+400)-...
kmplus*X(i+200)*X(i)^(4-m))-v*(X(i)-X(i-1))/h_body;
end
% DE for unsaturated hemoglobin in the blood over 200 spacial units
r(593)=-k0minus*X(593)+k0plus*(hbtotal-X(593)-X(793))*X(393)^m+...
kmminus*X(793)-kmplus*X(593)*X(393)^(4-m)-v*(X(593)-ihbm_fromwm)...
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/h_body;
for i=594:792
r(i)=-k0minus*X(i)+k0plus*(hbtotal-X(i)-X(i+200))*X(i-200)^m+...
kmminus*X(i+200)-kmplus*X(i)*X(i-200)^(4-m)-v*...
(X(i)-X(i-1))/h_body;
end
% DE for saturated hemoglobin in the blood over 200 spacial units
r(793)=-kmminus*X(793)+kmplus*X(593)*X(393)^(4-m)-v*...
(X(793)-ihb4_fromwm)/h_body;
for i=794:992
r(i)=-kmminus*X(i)+kmplus*X(i-200)*X(i-400)^(4-m)-v*(X(i)-...
X(i-1))/h_body;
end
% DE for partial pressure of co2 in the tissue over 200 spacial units
r(993)=dco2_tb_body*(X(993)-X(1193))/(sigma_co2*vbb)+d_ct*...
(X(994)-2*X(993)+X(993))/h_body^2+mu_co2_out*X(993);
for i=994:1:1191
r(i)=dco2_tb_body*(X(i)-X(i+200))/(sigma_co2*vbb)+d_ct*(X(i+1)-...
2*X(i)+X(i-1))/h_body^2+mu_co2_out*X(i);
end
r(1192)=dco2_tb_body*(X(1192)-X(1392))/(sigma_co2*vbb)+d_ct*(X(1192)-...
2*X(1191)+X(1191))/h_body^2+mu_co2_out*X(1192);

% DE for partial pressure of co2 in the blood over 200 spacial units
r(1193)=dco2_tb_body*(X(1193)-X(993))/(sigma_co2*vbb)+((1/sigma_co2)...
*(kcat_hco3*(X(1393)/(km_hco3+X(1393)))-kcat_co2*(sigma_co2*X(1193)/...
(km_co2+sigma_co2*X(1193)))))+d_ct*(X(1193)-ico2b_fromwm)/h_body^2;
for i=1194:1:1392
r(i)=dco2_tb_body*(X(i)-X(i-200))/(sigma_co2*vbb)+((1/sigma_co2)*...
(kcat_hco3*(X(i+200)/(km_hco3+X(i+200)))-kcat_co2*(sigma_co2*X(i)/...
(km_co2+sigma_co2*X(i)))))+d_ct*(X(i)-X(i-1))/h_body^2;
end

% DE for bicarbonate in the blood over 200 spacial units (123:142)
r(1393)=kcat_co2*(sigma_co2*X(1193)/(km_co2+sigma_co2*X(1193)))-...
kcat_hco3*(X(1393)/(km_hco3+X(1393)))-v*(X(1393)-ihco3_fromwm)...
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/h_body;
for i=1394:1:1592
r(i)=kcat_co2*(sigma_co2*X(i-200)/(km_co2+sigma_co2*X(i-200)))-...
kcat_hco3*(X(i)/(km_hco3+X(i)))-v*(X(i)-X(i-1))/h_body;
end

C.3.3

Calculating Distributions for Tissue and Blood Volumes

function [count_matrix,tbv_pairs,Y,Z] = Create_countmatrix_final(tot_random_num)
%This code creates a matrix of the bins that will be used for running the
%lung code for different size air and blood compartments. The intervals for
%air volume are [345,355],[355,365], etc with the middle of the interval
%being the number that is run in the code. This is similar for blood
%volumes, as [28,32],[32,36],... with the middle of the interval being the
%number that is run in the code.
%
%This code also creats the random vectors and calulates how many pairs
%exist in the bins we have created. This should only need to be done once
%and the final vector used forever, but this will repeat the process each
%time. We make it easy to ensure that you end up with the total number of
%random samples that you want.
%
%Always run this code with the file ’’Dist_for_air_and_blood_vols.mat’ in
%the same directory. This ensures that you do not need the statistics
%toolbox with your Matlab instillation in order for the code to work.
%
%tot_random_numbers should be set equal to the number of random numbers you
%want to count for each run of the lung code

A_left_limits=350:100:950;
A_right_limits=450:100:1050;
count_matrix_1(1:5)=A_left_limits(1)*ones(1,5);
for i=2:1:6;
count_matrix_1=[count_matrix_1 ones(1,5)*A_left_limits(i)];
end
count_matrix_2(1:5)=A_right_limits(1)*ones(1,5);
for i=2:1:6;
count_matrix_2=[count_matrix_2 ones(1,5)*A_right_limits(i)];
end
count_matrix=[count_matrix_1’ count_matrix_2’];
%%
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test_empty_CM=isempty(count_matrix);
if test_empty_CM==0;
B_left_limits=15:30:135;
B_right_limits=45:30:165;
count_matrix_3(1:5)=B_left_limits;
for i=2:1:6;
count_matrix_3=[count_matrix_3 B_left_limits];
end
count_matrix_4(1:5)=B_right_limits;
for i=2:1:6;
count_matrix_4=[count_matrix_4 B_right_limits];
end
end
count_matrix=[count_matrix count_matrix_3’ count_matrix_4’];
%% check
for i=1:1:length(count_matrix);
count_matrix(i,5)=(count_matrix(i,1)+count_matrix(i,2))/2;
count_matrix(i,6)=(count_matrix(i,3)+count_matrix(i,4))/2;
count_matrix(i,7)=i;
count_matrix(i,8)=0;
end
load(’Dist_for_air_and_blood_vols.mat’)
tbv_pairs(:,1)=random(t,tot_random_num,1);
tbv_pairs(:,2)=random(b,tot_random_num,1);

for i=1:1:tot_random_num;
for j=1:1:length(count_matrix);
if tbv_pairs(i,1)>=count_matrix(j,1) &&...
tbv_pairs(i,1)<count_matrix(j,2) &&...
tbv_pairs(i,2)>=count_matrix(j,3) &&...
tbv_pairs(i,2)<count_matrix(j,4)
count_matrix(j,8)=count_matrix(j,8)+1;
end
end
end
%% ERROR CHECK
if sum(count_matrix(:,8))~=tot_random_num;
error(’Error. \n Something is not right with the counting of your bins.’)
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end
%% Bar PLOT stuff
Y=350:10:1050;
Z=count_matrix(1:31,8);
for i=32:31:length(count_matrix);
Z=[Z count_matrix(i:i+30,8)];
end
Z=Z’;
bar3(Y,Z)
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